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Abstract 
Sympathetic nervous system (SNS) activity is elevated in some forms 
of essential hypertension. What causes sympathetic tone to be elevated, 
and how it mediates hypertension, however, is unclear. Angiotensin II 
(AngII) and a high dietary salt appears to be involved since in rats, 
chronic peripheral infusion of AngII induces a form of hypertension that 
is accompanied by increased indices of peripheral sympathetic tone 
selectively when they are fed a high sodium diet. Studies in this model 
have shown that contrary to prevailing views, peripheral sympathetic 
tone was diminished to the kidneys, but instead, suggested that it may be 
elevated selectively to the splanchnic vascular bed. Based on these 
findings, the initial aim of this thesis was to characterize, in conscious 
rats, the local hemodynamics within the splanchnic vascular bed and the 
role of the SNS in mediating changes in splanchnic vascular 
hemodynamics during AngII-salt hypertension. Studies were carried out 
to test the hypothesis that in addition to sympathetically mediated 
increases in splanchnic venous tone, AngII-salt hypertension was 
mediated by enhanced sympathetic vasoconstriction of splanchnic 
arterioles occurring through its peripheral sympathetic nerve supply.  
Splanchnic vascular resistance was found to be elevated in AngII-salt 
hypertensive rats; however, these hemodynamic changes occurred even 
after removal of direct sympathetic innervation to the splanchnic vascular 
bed by surgical denervation (celiac ganglionectomy). Furthermore, unlike 
previously shown, celiac ganglionectomy did not result in lowering of 
blood pressure during AngII-salt hypertension. Thus, contrary to the 
original hypothesis, changes in direct sympathetic input to the splanchnic 
vasculature did not mediate AngII-salt hypertension. Additional studies 
 iv 
in this thesis found that part of the problem with this inconsistent 
finding may be related to the technique commonly used to generate the 
model. Furthermore, studies in this thesis found, using chronic 
pharmacological adrenergic blockade, that the contribution of the SNS in 
AngII-salt hypertension may have been overestimated. Thus, the 
combined findings in this thesis and prior studies suggest that a fraction 
of AngII-salt hypertension is mediated by enhanced peripheral 
sympathetic tone, not through direct vasoconstrictive input to the 
splanchnic vasculature, but possibly via its influence on other non-renal 
splanchnic organs. 
 v 
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1.1 Rationale 
The renewed interest of targeting the sympathetic 
nervous system as a treatment for hypertension 
It’s been known through observational studies that the risk of death 
attributable to ischemic heart disease and stroke is related linearly to 
the level of blood pressure starting from a systolic blood pressure (SBP) 
of 115mmHg and a diastolic blood pressure (DBP) of 75mmHg (70). 
Because of this wide range, the definition of a high blood pressure as a 
“disease” is somewhat arbitrary. However, the public health burden of 
suboptimal blood pressure is clear; it shortens an individual’s life 
expectancy by as much as 5 years (43), and it has been reported to be 
the number one attributable risk of death throughout the world (21). 
 The current cutoff for classifying blood pressure levels as 
“hypertensive” is based on observational data showing that adults at 
low-risk of developing cardiovascular diseases can benefit from blood 
pressure lowering interventions to a target SBP < 140mmHg and DBP 
of < 90 mmHg (113). Under this definition, 50 million or more 
Americans is afflicted by the disease, with 2009 to 2010 prevalence 
estimated at 30.5% among men and 28.5% among women in the United 
States (48).  Worldwide, it is estimated that 972 million adults have 
hypertension, with the number predicted to rise to a total of 1.56 billion 
by 2025 (59). Given its current trend, hypertension is projected to be 
the single most important risk factor of cardiovascular diseases by the 
year 2020 (59).  
Despite improvements in pharmacological therapy seen in the past 
half-century and their efficacy in lowering blood pressure in many cases 
of hypertension, only 40% and 56% of hypertensive men and women, 
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respectively, have their blood pressure effectively controlled in the 
United States (48). Although factors such as patient compliance may 
play a role to this relatively poor control rate (20), this is also likely 
because the current understanding on the etiology of hypertension is 
incomplete as multiple physiological abnormalities driven by interactions 
between genetic, behavioral and environmental factors can cause 
hypertension (16).  
Although once controversial, there is now indisputable evidence that 
increased sympathetic nervous system activity (SNA) is one such 
physiological abnormality that plays a key role in the etiology of human 
hypertension (35). However, the clinical use of sympathetic nervous 
system (SNS) targeting therapies have been in decline, and has been the 
“forgotten pathway” in the treatment of hypertension (36). This is 
mostly because current pharmacotherapy not only block sympathetic 
control of arterial pressure, but many other functions as well, resulting 
in unwanted side effects and reduced patient compliance.  
This view has recently changed since the exciting recent 
demonstration in human patients of long-term antihypertensive 
responses to a novel device-based method of selective renal denervation 
(37, 105), fueling renewed interest in therapies targeting SNS in 
hypertension. In order to understand the physiological impact, efficacy, 
and potential benefit of such therapies to a wide range of hypertensive 
patients, however, would require a better understanding of how elevated 
SNA contributes to hypertension, specifically, by elucidating the 
principal effector organs of elevated SNA and the specific patterns of 
sympathetic outflow that result in the altered hemodynamic state.  
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Sympathetic target organs other than the kidneys 
may play an important role in hypertension 
It has long been thought that the principal effector organ of elevated 
SNA in neurogenic forms of hypertension is the kidney. Activation of 
sympathetic efferents to the kidney would favor salt and water 
retention, leading to expansion of blood volume and increase in blood 
pressure. Over time, autoregulatory changes in the peripheral 
vasculature would occur to counteract tissue overperfusion, resulting in 
elevated total peripheral resistance (TPR), a hallmark hemodynamic 
change in hypertension (72). Indeed, the rationale for targeting the renal 
nerves in recent clinical trials was largely based on this theory. This 
hypothesis initially appeared to be supported by the fact that arterial 
pressure is reduced for 2 years following a single renal denervation 
procedure (37, 105). However, in one case report in which SNA to 
skeletal muscle (MSNA) was measured before and after renal 
denervation, it was found to be reduced from 56 bursts/min before the 
procedure to 41 bursts/min 1 month later and 19 burst/min 1 year after 
the procedure (94). In addition, it has been shown in a recent case series 
of 35 patients with resistant hypertension that reductions in MSNA after 
renal denervation is more pronounced when measured at the single-unit 
level, compared to multi-unit MSNA (51). This observation, coupled 
with the fact that the magnitude of the decrease in whole body 
norepinephrine spillover following renal denervation cannot be explained 
by loss of renal efferent activity alone, suggests that the procedure 
decreases SNA to non-renal vascular beds as well (94).  
The mechanism by which renal denervation in humans lead to a 
reduction in peripheral sympathetic nerve activity is currently unknown. 
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One possibility that has been proposed is that renal denervation results 
in the destruction of renal afferent nerves which drive 
sympathoexcitation to other cardiovascular organs (94). This raises the 
possibility that part or majority of the antihypertensive response to 
renal denervation could be secondary to withdrawal of sympathetic tone 
to non-renal vascular bed.  
Studies in an experimental model of hypertension 
suggest the role of the splanchnic vascular bed as an 
important non-renal sympathetic target organ in 
hypertension 
Through experiments using the AngII-salt model of hypertension in 
rats, a neurogenic model for human hypertension, our group has recently 
uncovered the potential critical role for the sympathetic regulation of 
splanchnic vascular bed in the development of hypertension (64). 
Previous reports in humans support this finding and the possible role for 
the splanchnic vasculature in the development of hypertension. First, 
surgical splanchnicectomy was an effective treatment for hypertension 
prior to the advent of pharmacotherapy (100); and secondly, vascular 
resistance has been reported to be elevated in the hepatosplanchnic 
circulation before any other vascular bed in humans with borderline 
hypertension (102). Thus, elucidating the contribution of sympathetic 
control of the splanchnic vasculature in the development of experimental 
AngII-salt hypertension may provide further insights into the role of 
neural control of non-renal vascular beds in hypertension, and discovery 
of novel targeted therapies. 
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1.2 AngII-induced hypertension and the AngII-
salt model of experimental hypertension 
(NOTE: The first two sections has been previously published in a 
review article I have coauthored with John W. Osborn, PhD and 
Gregory D. Fink, PhD (86)) 
AngII-induced activation of the sympathetic nervous 
system is dependent on salt intake 
Hypertension caused by infusion of AngII in animals involves 
multiple control systems whose influence on arterial pressure is 
dependent on the dose of AngII as well as the presence of other factors 
such as salt intake (85, 87).  Doses of AngII that increase arterial 
pressure slowly over a course of days to weeks produce what is 
commonly referred to as the “slow pressor AngII” model.  It is thought 
that the hypertension is mediated, at least in part, by an elevated level 
of sympathetic nerve activity (SNA) (9, 38, 39). It has long been known 
that the severity of AngII-induced hypertension is directly dependent on 
the prevailing level of salt intake; and more recent studies suggest that 
the level of sympathoactivation is as well (63, 64). Thus, it is important 
to keep in mind that neurogenic mechanisms may not play an equally 
important role in “AngII-induced” hypertension in animals subjected to a 
normal or low salt intake as they would in those subjected to a high salt 
intake (“AngII-salt” hypertension).  
The salt-sensitive nature of AngII-induced hypertension often has 
been ignored in the literature, and this could account for the 
contradictory conclusions about the role of the sympathetic nervous 
system in the model. Two different methods for assessing the role of the 
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sympathetic nervous system in AngII-induced hypertension have 
commonly been employed: 1) changes in the depressor response to 
ganglionic blockade, and 2) changes in tissue or plasma norepinephrine 
(NE) concentration and turnover. These indices serve as an indicator for 
AngII induced changes in peripheral SNA, which can be generated at 
any level of the neuraxis. Changes in responses to ganglion blockade 
suggest changes in SNA effects on arterial pressure. However, it is 
important to note that changes in plasma NE and NE turnover do not 
necessarily reflect changes in SNA that directly affect arterial pressure. 
Our group and others have reported a 5-7 day delayed increase in the 
acute depressor response to ganglionic blockade in AngII-induced (13) 
and AngII-salt (63) models a finding consistent with the hypothesis that 
AngII hypertension is due, in part, to delayed activation of peripheral 
sympathetic outflow. In contrast, tissue NE has been reported to be 
regionally decreased in AngII-induced rats (65) and plasma NE 
unchanged in AngII-induced rabbits (11). A factor that may explain 
these disparate findings is that the level of sympathetic outflow 
measured by these indices during AngII-induced hypertension is highly 
dependent on the level of dietary salt intake. Our studies have 
demonstrated that both an increase in the response to ganglionic 
blockade and a parallel increase in whole body NE spillover is present in 
rats on a high but not a normal salt diet. These increases are not 
observed until 5-7 days of AngII administration (63, 64). These findings 
suggest that administration of AngII when combined with a high salt 
diet leads to a delayed enhancement of peripheral sympathetic outflow 
that contributes to, but does not exclusively cause, the associated 
hypertension. 
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The splanchnic vascular bed is the critical neural 
target in AngII-salt hypertension 
Another potential explanation for the disparate findings between 
laboratories regarding the contribution of the sympathetic nervous 
system to AngII-induced hypertension is a focus on the kidney as the 
most important sympathetic effector organ in long-term blood pressure 
regulation. This long-standing view stems from the kidney’s role in 
regulation of blood volume, which has been hypothesized to be directly 
linked to the long-term control of arterial pressure (49). The concept is 
supported by reports that renal denervation prevents some forms of 
experimental neurogenic hypertension (29, 56) as well as by recent 
studies showing that renal denervation results in sustained decreases in 
arterial pressure in humans with drug-resistant hypertension (95). 
However, it is important to note that these studies have not 
demonstrated that renal denervation decreases arterial pressure 
secondary to loss of efferent neural control of kidney function and 
subsequent changes in blood volume. To the contrary, there is a building 
consensus that the response of arterial pressure to renal denervation is 
due to destruction of sensory fibers from the kidney resulting in 
decreased SNA to other vascular beds such as skeletal muscle, as was 
recently reported in humans (94). 
In regard to the contribution of renal nerves to AngII-induced 
hypertension specifically, a number of studies have consistently found 
that renal SNA is decreased in this model, irrespective of salt intake. 
Indirect assessment of renal SNA in dogs suggested that it was 
decreased in AngII-induced hypertension (73), a finding that was later 
confirmed in rabbits in the first study to record SNA directly over a 
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period of weeks (4). We have recently reported similar results using 
direct long-term recording of renal SNA in AngII-salt rats (115). In 
addition, renal denervation does not prevent AngII-salt hypertension in 
the rat (64) or AngII-induced hypertension in the rabbit (13). Although 
these observations have been used as an argument against the role of the 
sympathetic nervous system in AngII-induced hypertension (82), this 
view assumes that the kidney is the only neural target that can result in 
hypertension and disregards the contribution of changes in sympathetic 
nerve activity to non-renal vascular beds to the pathogenesis of 
neurogenic hypertension.  
We have addressed this issue by utilizing a number of indirect and 
direct methods to assess the relative importance of SNA to renal and 
non-renal vascular beds in AngII-salt hypertension. Based on direct 
long-term recording of lumbar SNA and hind limb norepinephrine 
spillover (61, 115), as well as lumbar sympathectomy (Fink, unpublished 
observation), we conclude that SNA to skeletal muscle does not 
contribute to AngII-salt hypertension. On the other hand, in contrast to 
the finding that renal denervation has no effect on this model, 
denervation of the splanchnic vascular bed by celiac ganglionectomy 
(CGX) markedly attenuates the neurogenic phase of AngII-salt 
hypertension (64). This finding is consistent with an earlier study in 
which direct recording of splanchnic SNA revealed it was increased in 
AngII-induced hypertensive rats compared to normotensive controls 
(76). Collectively these studies demonstrate that SNA is differentially 
regulated in AngII-salt rats and, more importantly, suggest that the 
splanchnic vascular bed is the primary target of the sympathetic nervous 
system in this model of hypertension.  
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Hemodynamic mechanism by which an enhanced 
sympathetic vasomotor tone to splanchnic vascular 
bed contributes to AngII-salt hypertension 
The hemodynamic mechanism by which an increase in sympathetic 
vasomotor tone to the splanchnic vascular bed can lead to hypertension 
is partially uncovered and has been largely attributed to a reduction of 
vascular capacitance secondary to venoconstriction at the splanchnic 
vascular bed (62, 64). Decrease in venous capacitance would lead to a 
shift of blood volume from the venous to the less compliant arterial 
compartment of the circulation, resulting in a rise in arterial blood 
pressure (40).  It remains currently unknown, however, whether elevated 
SNA to the splanchnic vascular bed also mediates constriction of 
splanchnic resistance arteries. It has been shown in a select cohort of 
human prehypertensives that splanchnic vascular resistance is elevated 
(102). Given anatomical evidences that the majority of postganglionic 
nerves in the celiac-superior mesenteric ganglia dually innervate both 
veins and arteries (53), it is very likely that changes in SNA to the 
splanchnic vascular bed will result in changes both to veins and arteries. 
Thus, it is hypothesized that hypertension in this model is caused by a 
concerted action of reduced vascular capacitance and elevated total 
peripheral resistance due to sympathetically mediated constriction of the 
splanchnic vascular bed. 
1.3 Focus and organization of thesis 
The goal of this thesis was to further clarify the role of sympathetic 
vasomotor tone to the splanchnic vascular bed in the rat model of 
AngII-salt hypertension. This work was motivated by 3 main prior 
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findings discussed above: 1) vascular capacitance, a measure of systemic 
venous compliance of which the majority is determined by splanchnic 
venous tone, was decreased during AngII-salt hypertension, 2) reduction 
in vascular capacitance was reversible by ganglionic blockade, and 3) 
sympathetic denervation of splanchnic organs by celiac ganglionectomy 
(CGx) attenuated AngII-salt hypertension and prevented the reduction 
in vascular capacitance. These 3 findings, and other related work 
supporting the sympathoexcitatory role of AngII, led to the working 
hypothesis that AngII-salt hypertension in the rat is mediated, in part, 
by an increased sympathetic vasomotor tone to the splanchnic vascular 
bed, which elevates pressure by reducing vascular capacitance and 
increasing total peripheral resistance. A schematic view of this 
hypothesis is illustrated in Figure 1.1.  
The major limitation of the previous work was that the conclusions 
were mainly based on measures of whole body cardiovascular parameters 
coupled with targeted denervation to infer the role of sympathetic 
vasomotor tone to the splanchnic vascular bed.  To overcome this 
limitation, I devised a surgical technique for continuous monitoring of 
superior mesenteric artery blood flow, in addition to arterial pressure, in 
conscious, freely moving animals. This allowed for the monitoring of 
hemodynamic changes specifically at the splanchnic vascular bed and 
calculation of mesenteric vascular resistance, a direct index of splanchnic 
arteriolar tone.  
The work in this thesis was organized into 3 main chapters and a 
supporting chapter in the form of an appendix. In Chapter 2, I 
determined whether changes consistent with the hypothesis occur to 
splanchnic vascular resistance during AngII-salt hypertension. In 
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Chapter 3, I assessed whether changes in splanchnic vascular resistance 
were determined by sympathetic input to splanchnic vascular bed. 
Based on findings in Chapter 2 and 3, I reassessed the contribution of 
global sympathetic tone to the development of AngII-salt hypertension 
in Chapter 4. Finally, in Chapter 5, I provide a summary of all findings 
and implications to the original hypothesis.  
In Chapter 2, the AngII-salt model was generated by subcutaneous 
infusion of AngII using an implantable osmotic minipump. Observations 
in Chapter 2 warranted an optimization to the method of AngII delivery 
for improving the stability of the model. The results from this study are 
presented in Appendix 1. Studies in Chapters 3 and 4 were performed 
using the optimized method of AngII delivery based on results presented 
in Appendix 1. 
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1.4 Figures 
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Figure 1.1. Central Hypothesis 
 
Diagram depicting the central and peripheral neural pathways and 
major sympathetic end organs thought to be involved in the neurogenic 
mechanism of AngII-salt hypertension. We hypothesized that AngII and 
salt stimulate sympathetic premotor neurons in the brain leading to 
activation of peripheral sympathetic pathways in a site-specific manner. 
Prior studies have shown that renal and lumbar sympathetic nerve 
activities are decreased or unchanged, respectively, during AngII-salt 
hypertension. Additionally, cardiac denervation by stellate 
ganglionectomy has no effect on AngII-salt hypertension. These results 
suggest that sympathetic modulation of cardiac and renal function, and 
skeletal muscle vascular tone plays little or no role in the neurogenic 
mechanism of AngII-salt hypertension (see text). Indirect evidence 
suggests that splanchnic sympathetic nerves may be preferentially 
activated during AngII-salt hypertension, causing a reduction in 
splanchnic vascular capacitance, which increases effective circulating 
blood volume. Additionally, an increase in sympathetic outflow to the 
splanchnic vascular bed is also thought to increase splanchnic vascular 
resistance. The central hypothesis of this thesis is that these combined, 
sympathetically mediated changes in splanchnic vascular capacitance 
and resistance are the primary neurogenic mechanisms responsible for 
the sustained increase in arterial pressure during AngII-salt 
hypertension.  
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Figure 1.1 
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Chapter Overview 
Previous studies suggest that AngII-induced hypertension in rats fed 
a high salt diet (AngII-salt hypertension) has a neurogenic component 
dependent on an enhanced sympathetic tone to the splanchnic veins, 
and independent from changes in sympathetic nerve activity to the 
kidney or hind limb. The purpose of this study was to extend these 
findings and test whether altered autonomic control of splanchnic 
resistance arteries and the heart also contributes to the neurogenic 
component. Mean arterial pressure (MAP), heart rate (HR), superior 
mesenteric artery blood flow, and mesenteric vascular resistance (MVR) 
were measured during 4 control days , 14 days of AngII delivered 
subcutaneously (150ng/kg/min), and 4 days of recovery in conscious rats 
fed a high salt (HS; 2% NaCl) or low salt (LS; 0.1% NaCl) diet. 
Autonomic effects on MAP, HR and MVR was assessed by acute 
ganglionic blockade with hexamethonium (20mg/kg IV) on day 3 of 
control, days 1, 3, 5, 7, 10, and 13 of AngII, and day 4 of recovery. MVR 
increased during AngII infusion in HS and LS rats, but remained 
elevated only in HS rats. Additionally, the MVR response to 
hexamethonium was enhanced on days 10 and 13 of AngII selectively in 
HS rats. Compared to LS rats, heart rate in HS rats was higher during 
the 2nd week of AngII, and its response to hexamethonium was greater 
on days 7, 10 and 13 of AngII. These results suggest that AngII-salt 
hypertension is associated with delayed changes in autonomic control of 
splanchnic resistance arteries and the heart. 
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2.1 Introduction 
Under certain conditions, hypertension resulting from systemic 
administration of angiotensin-II (AngII-induced hypertension) is 
exacerbated by activation of the sympathetic nervous system (SNS). 
Our group and others have shown that salt intake is one such condition 
(79, 87).In rats fed a relatively high salt diet (2% NaCl), the level of 
blood pressure achieved in AngII-induced hypertension is significantly 
higher than in rats fed a normal salt diet (0.4% NaCl); this is associated 
with an increase in whole body norepinephrine (NE) spillover (63) and 
enhanced mean arterial pressure (MAP) responses to ganglionic blockade 
(62, 64). In contrast, these measures of whole body sympathetic tone in 
rats fed a normal salt diet remain near control levels.  
Despite increased “whole body” sympathetic tone in AngII-salt (i.e. 
those fed a high salt diet) hypertensive rats, we recently reported that 
sympathetic nerve activity (SNA) to the kidney and hind limb were 
reduced or unchanged, respectively (115). Suppression of renal SNA has 
also been directly measured during AngII-induced hypertension in 
rabbits (4) and indirectly in dogs (17), suggesting that this suppression 
is not a salt dependent effect, per se, but rather a baroreceptor mediated 
phenomenon. Indeed, the chronic AngII-induced decrease in renal SNA 
is not observed in sinoaortic denervated animals (3, 75). Additionally, 
AngII-induced hypertension is unaffected by sinoaortic denervation, 
suggesting that baroreflex mediated effects on renal SNA are not critical 
to the development of hypertension. Further evidence that renal SNA 
does not contribute to AngII-induced hypertension is that renal 
denervation has no effect on the final level of AngII-salt hypertension in 
rats (64), as well as AngII-induced hypertension in rabbits (13). 
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Combined, these latter results have been the major argument against 
the importance of the SNS in this form of hypertension (73).  
In contrast to changes in sympathetic control to the kidney, 
relatively little attention had been given to a possible role for elevated 
SNA to non-renal vascular beds in the pathogenesis of AngII-induced 
hypertension. Recent studies by King and Fink suggest that the SNS 
contributes to AngII-salt hypertension via an influence to the splanchnic 
vascular bed. Consistent with prior studies in AngII-salt hypertensive 
dogs (118), mean circulatory filling pressure (MCFP) was found to be 
elevated in AngII-salt hypertensive rats (62). Since the increase in 
MCFP was not associated with increased blood volume, this finding 
suggests that venomotor tone is elevated in AngII-salt rats.  
Furthermore, the elevated MCFP was sensitive to ganglionic blockade 
and prevented by splanchnic sympathectomy via celiac ganglionectomy. 
More importantly, this latter procedure attenuated AngII-salt 
hypertension to levels similar to those observed in AngII-induced 
hypertension in rats fed a normal salt diet (64).These findings suggest 
that the increase in MCFP during AngII-salt hypertension is secondary 
to sympathetically mediated venoconstriction in the splanchnic vascular 
bed causing a reduction in splanchnic vascular capacitance. Based on 
these findings, it has been proposed that the neurogenic reduction in 
splanchnic vascular capacitance contributes to higher levels of AngII-
induced hypertension in high salt rats by redistributing blood volume 
from the venous to the arterial circulation (40).  
Functional consequences of enhanced splanchnic SNA, however, are 
not restricted to veins. A question that remains unanswered is whether 
sympathetic vasoconstriction to splanchnic resistance arteries also is 
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enhanced during AngII-salt hypertension. This seems likely since 
labeling studies indicate that the majority of neurons in prevertebral 
ganglia (a major source of splanchnic sympathetic input) dually 
innervate arteries and veins (53). Thus, the proposed increase in 
sympathetic tone to the splanchnic vascular bed in AngII-salt 
hypertensive rats may exert its impact on blood pressure via enhanced 
constriction of splanchnic resistance arteries, as well as veins.  
We addressed this question in the present study by measuring 
arterial pressure (AP) and splanchnic blood flow continuously in 
conscious unrestrained rats before, during and after AngII 
administration in rats on a low or high salt diet. We hypothesized that 
AngII-induced increases in splanchnic vascular resistance, as calculated 
from measures of AP and splanchnic blood flow, would be greater in rats 
consuming a high salt diet compared to rats on a low salt diet.  
Moreover, we predicted that the neurogenic contribution to splanchnic 
vascular resistance during AngII administration, as assessed by the acute 
splanchnic vasodilation during ganglionic blockade, would be greater in 
high salt rats compared to low salt rats. 
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2.2 Materials and Methods 
2.2.1 Animal Subjects 
Male Sprague-Dawley rats (Charles River Laboratories International, 
Inc., Wilmington, MA) weighing ~ 270 to 370g (312±4g) were used for 
these experiments. Animal care and experimentation were performed in 
accordance with the National Institutes of Health Animals Use and Care 
Guideline based on a protocol submitted to, and approved by, the 
University of Minnesota Institutional Animal Care and Use Committee.  
2.2.2 Animal Instrumentation and Care 
Rats were housed in a temperature controlled environment with 12hr 
light-dark cycle and acclimatized to a high salt (2.0% NaCl) or low salt 
(0.1% NaCl) diet (Research Diets, Inc., New Brunswick, NJ) for at least 
7 days. On the day of surgery, rats were atropinized (0.2mg/kg, i.p., 
Baxter International, Inc., Deerfield, IL) and anesthetized with 
isoflurane (2% mixture in 100% O2, Baxter International, Inc.). 
Gentamicin (0.05ml, i.m., Hospira, Inc., Lake Forest, IL) was given pre-
surgically for antimicrobial prophylaxis. Surgery was performed using 
aseptic techniques. An arterial pressure telemeter (TA11PA-C40, Data 
Sciences International (DSI), Saint Paul, MN) was implanted as 
previously described (110). A venous catheter made from a 7cm segment 
of Silastic® tubing (508-001, 0.3mm I.D., 0.64mm O.D., Dow Corning, 
Corp., Midland, MI) attached to a 75cm Tygon S-54HL medical catheter 
(AAQ04103, 0.60mm I.D., 1.52mm O.D., Saint-Gobain Performance 
Plastics, Corp., Akron, OH) was implanted into the inferior vena cava 
via the left femoral vein. A 1mm Transonic flow probe (MC-1PRS-JS, 
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Transonic Systems, Inc., Ithaca, NY) was placed on the superior 
mesenteric artery (SMA) approached retroperitoneally though an 
incision at the left flank. The venous catheter and the flow probe cable 
were tunneled subcutaneously and exteriorized through an incision made 
at the level of the scapulae. A tether anchor made from a circular piece 
of surgical polyester mesh (PETKM14002, Textile Development 
Associates, Inc., Surgical Mesh Division, Brookfield, CN) attached to a 
silicone rubber catheter, (51135K78, McMaster-Carr, Co., Elmhurst, IL) 
was sutured to the skin at the incision over the scapulae. A 38cm 
stainless steel spring (Exacto Spring, Corp., Grafton, WI) was threaded 
halfway into the silicone portion of the tether anchor. The venous 
catheter and flow probe cables were externalized through this spring.  
Rats were then housed individually in a custom made Plexiglass® 
cylindrical cage and tethered via the spring attached to an electrical 
swivel (SVL6C, Kent Scientific, Corp., Torrington, CT) suspended 
above the cage. At least 10 days were given for recovery. During this 
time, food and water intake were monitored along with signs of 
appropriate recovery from surgery. A combination of ampicillin 
(50mg/kg sid, i.v., Sandoz International, GmbH, Holzkirchen, 
Germany), tobramycin (3mg/kg sid, i.v., Teva Pharmaceuticals USA, 
Irvine, CA), and buprenorphine (0.05mg/kg bid, i.v., Reckitt Benckiser 
Pharmaceuticals, Inc., Richmond, VA) was given for antimicrobial 
prophylaxis and analgesia during the first 3 days of recovery.  
2.2.3 Experimental Protocol 
The experimental protocol was conducted in 2 groups: high salt (HS; 
N=10) and low salt (LS; N=10) rats. AP and superior mesenteric artery 
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blood flow (MBF) were continuously measured throughout the 22 day 
protocol. At the end of a 4 day control period, AngII was administered 
for 14 days at a rate of 150ng/kg/min using ALZET osmotic pumps 
(2ML2, DURECT, Corp., Cupertino, CA) implanted subcutaneously. On 
the morning after the 14th day of AngII, rats were anesthetized with 
isoflurane, the minipump was removed, and animals were returned to 
their cage for an additional 4 days of measurements (recovery period).  
Assessment of autonomic control of MAP, heart rate (HR), and 
mesenteric vascular resistance (MVR) during AngII infusion was 
performed by ganglionic blockade on days 1, 3, 5, 7, 10, and 13 of AngII, 
and compared to values obtained on the 3rd day of control and 4th day 
of recovery. Ganglionic blockade was achieved by intravenous 
administration of hexamethonium (H0879, Sigma-Aldrich, Co., St. 
Louis, MO) at a dose of 20mg/kg (93). Animals were weighed in the 
morning on the day of the experiment and injections were performed in 
the afternoon between 3 and 6 PM. At least 30 min. after the injection, 
the i.v. catheter was flushed with saline containing 50U/mL heparin 
(Sagent Pharmaceuticals, Inc., Schaumburg, IL).  
2.2.4 Data Acquisition and Analysis 
The AP and MBF signals were collected continuously at 500Hz using 
DSI software (Dataquest ART v.4.0 Platinum, DSI). The AP signal was 
acquired using a wireless receiver (RPC-1, DSI), and the MBF signal 
was acquired using a dual channel flow meter (T206, Transonic Systems, 
Inc.) connected to an analogue to digital converter box (C11V, DSI). 
MAP, HR, and mean MBF was calculated on-line from consecutive 10s 
segments of the pulsatile waveform and stored to disk. These data were 
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imported into MATLAB (v.R2009b, The Mathworks, Inc., Natick, MA) 
for calculating MVR, averaging daily hemodynamic values, and 
analyzing the ganglionic blockade data. MVR was calculated off-line 
from the MAP and mean MBF data as MAP/MBF. 12hr averages of 
MAP, HR, MBF, and MVR was calculated starting from the beginning 
of the dark cycle on day 0 of the protocol after removal of the 4hr 
segments immediately following ganglionic blockade. To determine the 
response to ganglionic blockade, data was first smoothed with a 3rd 
order median filter. The peak/trough response of MAP, HR or MVR 
was determined on this smoothed dataset and subtracted from the 
average of the 10min baseline period (see Figure 1).  
2.2.5 Statistical analysis 
Variables in HS and LS rats were analyzed by factorial ANOVA. The 
effect of dietary salt intake and AngII administration, on the 12hr mean 
hemodynamic values for each light-dark cycle, and response to 
ganglionic blockade was analyzed by two-way repeated measures 
ANOVA using SigmaStat (v.3.5, Systat Software, Inc., San Jose, CA). A 
significant interaction or main effect was further analyzed by post-hoc 
multiple comparisons with respect to the control samples for each factor 
(low salt for diet, and control day 3 for day of protocol) using the Holm-
Sidak method. A p < 0.05 was considered statistically significant. 
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2.3 Results 
Figure 1 shows a typical trace of the pulsatile AP and MBF 
waveform from a single HS rat taken during control. MBF data was of 
high fidelity (as shown by the pulsatile flow profile at each cardiac 
cycle), and allowed for determination of absolute flow rate to the 
mesenteric vascular bed throughout the entire 22 days of the protocol. 
Also shown in the figure are the 10s mean AP, MBF, and HR traces 
calculated from the waveform data, and the MVR trace calculated from 
the 10s mean AP and MBF data points. These 10s mean data were used 
to determine the responses to ganglionic blockade and changes in 12hr 
hemodynamics before, during, and after AngII treatment in HS and LS 
rats. 
2.3.1 Effect of AngII on 12hr hemodynamics in rats 
fed a high or low salt diet 
Figure 2 shows the daily 12hr average MAP, MBF, MVR and HR for 
the entire 22 days of the protocol. Rats were allowed to recover from 
surgery (typically 10 days) until a distinct circadian rhythm was 
observed in every variable during baseline. There were no differences in 
the 12hr MAP, MBF, MVR or HR during the 4 day control period 
between HS and LS rats. All variables recovered to control levels 
following 14 days of AngII. There were no differences in the 12hr 
hemodynamic values during the 4 day recovery period between HS and 
LS rats except for the nighttime MAP on the second day of recovery. 
MAP was identical in both groups during the first 24hr of AngII 
administration. However, whereas MAP reached a plateau in LS rats by 
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the first day of AngII infusion, MAP did not reach steady state until the 
second week of AngII in HS rats. The steady state level of MAP 
(averaged over days 10 thru 13 of AngII) was 162±2mmHg and 
119±2mmHg for HS and LS rats, respectively, during nighttime, and 
149±2mmHg and 117±2mmHg for HS and LS rats, respectively, during 
daytime.   
 MBF decreased transiently during the initial stage of AngII 
infusion in both HS and LS rats and this decrease was similar in 
magnitude. Similarly, MVR increased to the same magnitude during this 
time in both groups. Following the acute drop, MBF gradually returned 
towards control levels in both HS and LS rats. Although there were no 
between group differences in MBF on a day to day basis throughout the 
protocol, the recovery of MBF, compared to the within group control 
levels, took 5 days in HS rats compared to 2 days in LS rats.  
Changes in MVR following the peak at day 1 of AngII deviated 
significantly between HS and LS rats. In HS rats, higher MVR levels 
persisted until removal of AngII, while in LS rats, MVR sharply dropped 
following the day 1 peak and gradually returned toward control levels. 
MVR in LS rats during AngII infusion was no longer statistically 
significant from control after day 6 of AngII. MVR averaged over days 
10 thru 13 of AngII was 14.3±0.7mmHg*min/mL and 
9.5±0.4mmHg*min/mL in HS and LS rats, respectively, during 
nighttime, and 14.9±0.7mmHg*min/mL and 10.5±0.5mmHg*min/mL in 
HS and LS rats, respectively, during daytime. Removal of the minipump 
on day 14 of AngII caused an acute drop in MVR toward control levels 
in HS rats.  
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Administration of AngII resulted in an initial bradycardic response 
that was more pronounced in HS than LS rats. There was a clear trough 
for this response in HS rats at the end of day 4 of AngII but then HR 
gradually rose toward control levels.  In contrast, HR in LS rats 
remained at levels slightly below control thru day 11 of AngII. HR, both 
nighttime and daytime, on days 9, 10, 11, and 12 of AngII was higher in 
HS rats compared to LS rats, although these levels in HS rats were not 
statistically distinguishable from their own control.  
2.3.2 Effect of AngII on the hemodynamic responses 
to acute ganglionic blockade in rats fed a high or low 
salt diet 
Figure 3 summarizes the results from the ganglionic blockade 
experiments and shows the change in the contribution of autonomic tone 
to basal hemodynamics before, during and after AngII administration. 
During the control period there was no difference in the depressor 
response to hexamethonium between HS and LS rats. However, the 
depressor response to hexamethonium in HS rats increased starting at 
day 3 of AngII with this trend continuing until day 13 of AngII. In 
contrast, the depressor response to hexamethonium in LS rats was 
indistinguishable from control levels throughout the protocol. The 
depressor response to hexamethonium returned to control levels after 
removal of the minipumps in both HS and LS rats. 
 The MVR responses to hexamethonium showed a pattern similar 
to those observed with MAP in that responses increased during AngII 
administration in HS salt rats but not in LS rats. Specifically, there 
were no differences during the control period between HS and LS rats. 
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There were no between group differences in the MVR response to 
hexamethonium during the first week of AngII except for day 3 of AngII 
where the response was significantly higher in HS rats. By days 10 and 
13 of AngII, the MVR response to hexamethonium was significantly 
higher in HS compared to LS rats. The response of MVR to 
hexamethonium returned to control levels by the 4th day of the recovery 
period and was not different between groups.  
 HR dropped in response to hexamethonium in both groups to a 
similar degree during control, and this was not different between groups. 
However, on day 3 of AngII, the HR response to hexamethonium 
switched from a bradycardia to a tachycardia in HS rats in contrast to 
LS rats, which did not change. As observed in the responses of MAP 
and MVR, the HR response to hexamethonium during the second week 
of AngII was significantly higher in HS rats compared to LS rats. In LS 
rats, the HR response to hexamethonium tended to gradually decrease in 
magnitude over time, however, these changes were not statistically 
different from control levels. The HR responses to hexamethonium in HS 
rats were greater than those measured in LS rats on days 7, 10, and 13 
of AngII, however, these values were not statistically different from the 
within group control period. Finally, the HR response to 
hexamethonium measured on the 4th day of the recovery period was 
similar between HS and LS rats, and not different from their respective 
within group control periods. 
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2.4 Discussion 
Rats subjected to the AngII-salt protocol, where they are fed a high 
salt diet during continuous infusion of AngII, have been shown to 
develop hypertension by multiple mechanisms including a delayed 
increase in “whole body” sympathetic activity (62, 63). Consistent with 
these previous findings, AngII-induced hypertension in our current study 
was significantly higher in HS compared to LS rats, and there was a 
delayed increase in the depressor response to hexamethonium in HS rats 
but not LS rats (62). Previous findings that celiac ganglionectomy 
attenuates the development of AngII-salt hypertension suggested that 
the splanchnic vascular bed is a significant contributor to the neurogenic 
component of hypertension in this model (64). Furthermore, direct 
measurement of renal and lumbar SNA, which were previously found to 
be slightly below or unchanged from baseline (115), suggested that the 
sympathoexcitatory response in the AngII-salt model is a regionally 
localized phenomenon. Although SNA to the splanchnic vascular bed has 
not been directly measured in AngII-salt rats, the evidence reported here 
supports a role for splanchnic sympathetic nerves in mediating 
peripheral hemodynamic changes that ultimately contribute to the 
severity of hypertension in this model.   
To date, the only finding that provides a mechanistic insight into the 
hemodynamic effect of a localized increase in sympathetic tone to the 
splanchnic vascular bed during AngII-salt hypertension has been the 
observation that MCFP is elevated in this model, which has been shown 
to be progressively more sensitive to ganglionic blockade and dependent 
on an intact sympathetic innervation to the splanchnic vascular bed (62, 
64). Our present study extends these findings by showing that 
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continuous infusion of AngII results in a sustained increase in MVR 
associated with an elevated MVR response to ganglionic blockade in HS 
but not LS rats (62). This new finding adds further support to the 
overall hypothesis that the higher level of dietary salt contributes to the 
severity of AngII-induced hypertension in HS rats by increasing 
sympathetic vasoconstrictor tone to the splanchnic vascular bed. This 
appears to contribute to the hypertension by increasing splanchnic 
vascular resistance and reducing splanchnic vascular capacitance, and 
through their expected overall impact on total peripheral resistance 
(TPR) and effective circulating blood volume. These combined effects 
would elevate arterial pressure by effectively translocating blood from 
the high compliant venous compartment to the less compliant arterial 
compartment as suggested in a recent review (40).  
The increase in sympathetic tone during AngII-salt hypertension is 
delayed, as suggested by the timing at which measurable changes in 
whole body NE spillover occur (week 2 of AngII) (63), but more 
importantly, its contribution to arterial pressure is progressive, as 
suggested by the time course in which the depressor response to 
ganglionic blockade increases, starting at around day 3 of AngII.  The 
current study suggests that the neurogenic influence on the splanchnic 
vasculature also occurs in a time-dependent manner.  The contribution 
of neurogenic tone to MCFP (which is largely determined by splanchnic 
venous capacitance) was increased as early as one day after initiating 
the infusion of AngII (62). In the present study, although the magnitude 
of mesenteric vasodilation during ganglionic blockade was increased 3 
days after the start of AngII infusion, it was not consistently elevated 
until the 10th day of AngII. This difference in the timing of the onset of 
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sustained neurogenically mediated increases in MCFP (day 1 of AngII) 
and MVR (day 10 of AngII) may be the result of a gradually increasing 
peripheral sympathetic tone in AngII-salt rats. For instance, the 
threshold for a functional response to increased sympathetic tone may 
be different in splanchnic veins and arteries. It has been reported that 
the frequency-response curve to nerve stimulation is shifted to the left 
(i.e. lower frequency) for splanchnic veins compared to splanchnic 
arteries (33). Thus, it is possible that splanchnic SNA increases 
gradually during AngII infusion, and that earlier and lower frequencies 
of sympathetic nerve discharge during AngII infusion in HS rats affect 
mostly the splanchnic veins, while later and higher frequencies of 
sympathetic discharge affects both veins and arteries. Thus a progressive 
increase in the levels of SNA and differential responses of splanchnic 
resistance and capacitance vessels may be the underlying mechanism for 
the progressive rise in MAP seen in HS rats treated with AngII. It is 
important to note, however, that there are several other possibilities to 
explain this observation, including changes in arterial reactivity to NE 
and release of vasodilators, which may counter the early constrictor 
effects of increased SNA to splanchnic resistance arteries. Further 
studies are necessary to establish more certainly the mechanism behind 
the progressive change in the sympathetic contribution to arterial 
pressure during AngII-salt hypertension.  
In addition to changes in sympathetic vasoconstrictor tone in the 
splanchnic vascular bed, non-neurogenic vasoconstrictor mechanisms to 
the splanchnic and potentially other vascular beds appear to play a role 
in AngII-induced hypertension. For instance, the MVR peak on day 1 of 
AngII, and the early differences in MVR between HS and LS rats 
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starting at day 2 cannot be explained by an elevated sympathetic 
vasoconstrictor tone since MVR responses to ganglionic blockade were 
not consistently elevated until day 10 of AngII. The initial increase in 
MVR in both HS and LS rats may be a result of direct vasoconstrictor 
effects of AngII; the early differences in MVR between HS and LS rats 
may reflect differences in the compensatory responses triggered in 
response to the initial vasoconstriction and rise in MAP, or altered 
reactivity of mesenteric arteries to AngII. It has been shown that high 
salt intake can increase the reactivity of cremasteric arterioles to AngII 
(44). Whether similar dietary salt-dependent sensitization occurs in 
mesenteric arterioles is unknown, but the initial increase in MVR in 
response to AngII infusion was similar between HS and LS rats 
suggesting that any effect of sensitization to AngII mediated 
vasoconstriction was small. Furthermore, the sustained increase in MAP 
in LS rats during AngII infusion despite a return of MVR to control 
levels indicates that there is a persistent non-neurogenic vasoconstrictor 
stimulus to non-splanchnic vascular beds. The effects of AngII on the 
renal vascular bed are well known and likely play a prominent role in 
the non-neurogenic mechanisms underlying AngII-induced hypertension. 
In this study, we also assessed whether autonomic tone to the heart 
increases during AngII-salt hypertension. Although HR was higher and 
the bradycardic response to ganglionic blockade more prominent in HS 
compared to LS rats during the second week of AngII infusion, these 
levels in HS rats were not statistically higher compared to their own 
control levels. Similarly, the HR response to ganglionic blockade in LS 
rats during the second week of AngII infusion were not statistically 
different compared to control, making it difficult to draw conclusions 
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from the between group differences found in this study. Nevertheless, it 
is possible that the difference in baseline HR between HS and LS rats 
during the second week of AngII is due to an inappropriate balance of 
sympathetic and parasympathetic cardiac autonomic activity. Although 
further studies are necessary to determine the role of cardiac 
sympathetic nerves in AngII-salt hypertension, preliminary findings in 
cardiac denervated rats and rats chronically treated with atenolol 
suggest that changes in sympathetic tone to the heart play little or no 
functional role in the neurogenic component of AngII-salt hypertension 
(52). It is clear however, that baseline HR is initially suppressed during 
AngII-induced hypertension, as shown by the tachycardic response to 
ganglionic blockade on day 3 of AngII in HS rats. This initial decrease in 
sympathetic tone (and/or increase in parasympathetic tone) to the heart 
is likely baroreflex mediated, which is consistent with previous studies 
showing that renal SNA is initially suppressed during AngII-induced 
hypertension in a baroreflex dependent manner (3, 75). Suppression of 
sympathetic activity to the heart and renal SNA is not seen with 
sympathetic effects on splanchnic resistance arteries and lumbar SNA 
(115), suggesting that there is a region-specific difference in the degree 
of baroreceptor inhibition of sympathetic tone in response to the initial 
phase of AngII hypertension. This hypothesis of minimal baroreflex 
control of SNA to the splanchnic vascular bed relative to neural control 
of the heart, kidney or hind limb skeletal muscle needs to be tested in 
further studies. 
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2.4.1 Strengths and Limitations of the Study 
To our knowledge, this study is the first to employ direct continuous 
long term recording of superior mesenteric artery blood flow and AP in 
conscious unrestrained animals before, during and after the induction of 
any model of experimental hypertension. The combination of this 
approach, with intermittent assessment of neural control of splanchnic 
hemodynamics using ganglionic blockade, has generated novel results 
regarding the role of neural control of this vascular bed in the 
pathogenesis of AngII-salt hypertension. The strength of this approach is 
the ability to assess neural control of a specific vascular bed over a long 
period of time using a repeated measures experimental design. Although 
we did not directly measure SNA to the splanchnic vascular bed, a key 
variable of interest was calculated, i.e. mesenteric vascular resistance.  
Ganglionic blockade has been a standard technique for determining 
the contribution of the SNS to AP and regional hemodynamics, and it 
has been shown that the peak response is relatively unaffected by 
compensatory release of hormones (e.g. vasopressin) in response to the 
rapid hypotensive effect (93). Nevertheless, results must be interpreted 
with caution (81). Although we feel that an increase in SNA to the 
splanchnic vascular bed is the most likely explanations for the obtained 
results, other possibilities exist. One is that the response to ganglionic 
blockade is a reflection of a generalized increase in sensitivity to 
vasoconstrictors due to “vascular amplifier” effect secondary to AngII-
induced vascular hypertrophy (47). Another possibility is a withdrawal 
of myogenic tone in response to a drop in pressure secondary to 
withdrawal of sympathetic tone elsewhere. Finally, AngII may amplify 
nerve transmission at the sympathetic ganglia, post-ganglionic pre-
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synaptic nerve terminal and vascular neuroeffector junction (90), which 
could result in sympathetic nerve dependent changes in the splanchnic 
vascular bed without an actual increase in nerve activity. Thus, further 
experiments, such as those measuring MVR in celiac ganglionectomized 
rats and directly recording splanchnic SNA, are needed to determine 
whether enhanced sympathetic vasomotor nerve activity to the 
splanchnic vascular bed was responsible for the observed changes in 
MVR.   
However, several studies argue against these alternate possibilities. 
For example, it has been shown that prevention of vascular hypertrophy 
does not affect AngII-induced hypertension, suggesting that AngII-
induced hypertension is not solely due to development of vascular 
amplifiers (32).  Second, since sympathetic nerves to two major vascular 
beds, the hind limb and kidney, do not play a role in AngII-salt 
hypertension (64, 115), the depressor response to ganglionic blockade is 
most likely due to inhibition of vasomotor tone to the splanchnic 
vascular bed. Taken together these findings strongly support the idea 
that decrease in MVR following ganglionic blockade in AngII-salt rats is 
due to a decrease in sympathetic tone rather than autoregulatory 
responses secondary to withdrawal of sympathetic tone to other vascular 
beds.  
Although the AngII-induced hypertension model has been a popular 
model for the study of both neurogenic and non-neurogenic mechanisms 
of hypertension, the protocols employed in the literature are highly 
variable both between species and within species. Importantly, the 
mechanisms that participate and predominate in the hypertension 
generated by infusion of AngII appears to be highly dependent on the 
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administered dose (97) and the level of dietary salt (79). Although our 
protocol generates a model of salt sensitive hypertension dependent on a 
neurogenic mechanism at high levels of salt intake, others, such as that 
of Luft and coworkers, have reported a significant neurogenic component 
in rats given a higher dose of AngII but fed a normal salt diet (76). It is 
possible that higher levels of AngII would offset the threshold for dietary 
salt levels required to activate the neurogenic response. Despite these 
differences, it appears that the splanchnic sympathetic nerves play a 
prominent role when a neurogenic mechanism is activated during AngII-
induced hypertension as shown by our studies and studies by Luft and 
colleagues which reported increases in directly measured splanchnic SNA 
in their model of AngII-induced hypertension (76).  
2.4.2 Perspectives 
What is the clinical relevance of a delayed change in autonomic tone 
in the AngII-salt model of hypertension? In our view, it demonstrates 
that there is a clear role for the autonomic nervous system during 
established phase of salt sensitive forms of hypertension. Although 
several mechanisms contribute to hypertension in the AngII-salt model, 
the neurogenic component activated not only exacerbates the 
hypertension, it also likely participates in inducing end organ damage 
and augmenting cardiovascular risk in general. Furthermore, our studies 
highlight the fact that neurogenic mechanisms underlying some forms of 
hypertension may not be limited to effects on the kidneys alone. Our 
results in fact indicate that changes in sympathetic control of splanchnic 
vascular resistance and capacitance dominate the neurogenic component 
of AngII-salt hypertension (40). Whether the splanchnic vascular bed is 
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an important sympathetic target in other salt-sensitive forms of 
hypertension is yet to be determined. A better understanding of the 
contribution of organ specific changes in sympathetic nerve activity to 
neurogenic forms of hypertension could lead to development of new 
targeted approaches for the treatment of  hypertension in the human 
population, such as those recently demonstrated using catheter based 
renal denervation (37). 
 
  
 38 
Grants 
Funded by a National Heart, Lung, and Blood Institute grant (R01 
HL076312) awarded to the Neurogenic Cardiovascular Diseases 
Consortium. MTK is supported by an AHA Predoctoral Fellowship 
award (11PRE7810000). 
 
Disclosures 
None 
  
 39 
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Figure 2.1. Original tracing for typical AP, MBF, 
MVR, and HR response to ganglionic blockade 
 
Representative traces for the responses of AP, MBF, MVR and HR 
to ganglionic blockade in a single rat during control. AP and MBF 
signal was sampled and saved to disk continuously at 500Hz (dark grey). 
Mean AP, MBF and HR was calculated and saved every 10sec during 
acquisition (light grey for AP and MBF, dark grey for HR). MVR was 
calculated from the 10sec mean AP and MBF data as AP/MBF. The 
peak response of AP, MVR and HR after injection of hexamethonium 
was determined with respect to baseline (average of 10min immediately 
preceding injection).   
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Figure 2.1 
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Figure 2.2. Change in MAP, MBF, MVR, and HR 
during 2wk AngII infusion in high and low salt rats 
 
12hr average HR, MAP, MBF and MVR for HS (n=10), and LS 
(n=10) rats during 4 days of control, 2 weeks of AngII infusion, and 4 
days of recovery following cessation of AngII infusion. AngII was given 
via osmotic minipumps implanted subcutaneously after the control 
period, and removed after 14 days. Changes in MBF are comparable 
between HS and LS rats. ( ,   denote within group statistical 
significance compared to daytime or nighttime values from day 4 of 
control at an α < 0.05 for HS or LS rats, respectively. Statistical 
significance for nighttime or daytime values is denoted by  , or  , 
respectively, which are placed on the top or bottom corner at the right 
side of each graph.  ,  denote between group statistical significance 
at an α < 0.05 for nighttime or daytime values, respectively, compared 
to values from LS rats used as control.) 
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Figure 2.2 
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Figure 2.3. MAP, MVR, and HR response to acute 
ganglionic blockade during AngII induced HTN in 
high and low salt rats 
 
HR, MAP, and MVR response to acute ganglionic blockade for HS 
(n=10) and LS (n=10) rats on control day 3, AngII days 1, 3, 5, 7, 10, 
and 13, and recovery day 4. ∆HR, MAP, and MVR were calculated by 
subtracting the peak/trough values after ganglionic blockade from the 
10min. baseline period immediately preceding the injection.  denote 
within group statistical significance compared to day 3 of control at an α 
< 0.05 for HS rats  denote between group statistical significance at an 
α < 0.05 compared to values from LS rats used as control. ) 
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Figure 2.3 
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Chapter Overview 
A previous study showed that celiac ganglionectomy (CGx) 
attenuates AngII-salt hypertension by preventing a sympathetic 
mediated reduction in splanchnic vascular capacitance. We have 
subsequently shown that splanchnic vascular resistance is elevated 
during AngII-salt hypertension; a response that was reversible by acute 
ganglionic blockade. We hypothesized that CGx attenuates AngII-salt 
hypertension by preventing a sympathetically mediated rise in 
splanchnic vascular resistance. In the present study we measured mean 
arterial pressure (MAP), heart rate (HR), superior mesenteric artery 
blood flow (MBF), and mesenteric vascular resistance (MVR) in Sham 
and CGx treated rats fed a 2% NaCl diet subjected to 14 days of AngII 
infusion. Autonomic effects on MAP, MVR, and HR was assessed by 
ganglionic blockade (hexamethonium) during control and days 1, 3, 5, 7, 
10, and 13 of AngII. CGx rats had a lower baseline MAP and MVR, and 
higher HR and MBF compared to Sham. However, CGx had no effect on 
the rise in MAP during AngII infusion or the acute depressor response 
to hexamethonium. MVR rose in both Sham and CGx rats during AngII 
infusion. MVR stabilized at a slightly lower level in CGx rats, in part 
due to lower control levels, but this had no effect on the MAP response. 
CGx had no effect on the acute response of MVR to hexamethonium. 
These results suggest that changes in MVR during AngII-salt 
hypertension are primary mediated by non-neurogenic mechanisms, and 
that previously reported effect of CGx may not be due to sympathetic 
denervation of the splanchnic vasculature alone. 
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3.1 Introduction 
Hypertension resulting from systemic administration of angiotensin-II 
(AngII) in conjunction with a high salt diet, i.e. AngII-salt hypertension, 
is associated with an increase in whole body norepinephrine (NE) 
spillover (63) and a progressive rise in the hypotensive response to acute 
ganglionic blockade (62, 64, 66). Combined, these results suggest that 
AngII-salt hypertension is mediated, in part, by an increase in peripheral 
sympathetic tone. However, direct recording of sympathetic nerve 
activity (115) in conscious rats has shown that renal and lumbar 
sympathetic nerve activity (SNA) is depressed or unchanged, 
respectively, during AngII-salt hypertension, suggesting that the 
peripheral target of enhanced sympathetic tone is neither the kidneys 
nor skeletal muscle.  
Neurogenic constriction of capacitance vessels has been proposed as a 
potential mechanism contributing to AngII-salt hypertension (40). It has 
been shown that mean circulatory filling pressure (MCFP), a function of 
total blood volume and systemic vascular capacitance, is elevated in this 
model and reversible by acute ganglionic blockade. Since there are no 
measurable changes in total blood volume during AngII-salt 
hypertension, it has been hypothesized that the increase in MCFP is 
mediated by enhanced sympathetic tone to capacitance vessels, 
primarily in the splanchnic vascular bed (62). Consistent with this 
hypothesis, King and Fink have shown that surgical sympathectomy of 
the splanchnic vascular bed by celiac ganglionectomy (CGx) not only 
prevents the rise in MCFP in AngII-salt rats, but significantly 
attenuates hypertension in this model (64). These findings provided 
further support for the hypothesis that AngII-salt hypertension is 
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mediated, in part, by enhanced sympathetic tone to the splanchnic 
vascular bed.  
We recently measured arterial pressure and superior mesenteric 
artery blood flow (MBF) continuously, before and during AngII-induced 
hypertension in rats consuming a high salt diet. Consistent with the 
original hypothesis, mesenteric vascular resistance (MVR) and mean 
arterial pressure (MAP) increased in parallel in AngII-salt rats, and 
both responses were acutely reversible by ganglionic blockade (66). This 
provided further evidence, using a more localized index of splanchnic 
vascular tone in conscious freely moving animals, that sympathetic tone 
is increased to the splanchnic resistance vessels of AngII salt rats.  
Our recent finding that the chronic increase in MVR in AngII-salt 
rats can be acutely reversed by ganglionic blockade is consistent with 
the hypothesis that AngII-salt hypertension is driven by sympathetic 
input to the splanchnic vascular bed. If this is true, we predicted that 
chronic sympathetic denervation of the splanchnic vascular bed, by 
CGx, should prevent the increase in MVR in AngII-salt rats. The 
present study was designed to test this hypothesis. 
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3.2 Methods 
Experiments were performed in conscious, chronically instrumented 
rats in accordance with NIH guidelines. All experimental procedures 
were conducted after approval and under supervision by the institutional 
animal care and use committee of the University of Minnesota. 
3.2.1 Animal use and care 
28 male Sprague-Dawley rats from Charles River Laboratories 
(Wilmington, MA) weighing 226-275g were used in this study. Upon 
arrival, rats were switched to a 2% NaCl diet (Research Diets Inc., New 
Brunswick, NJ) and housed 2 per cage in a 12-12hr light-dark cycled 
room (8:30/20:30 cycle). Distilled water was available ad-libidum. 
Animals were allowed to acclimate 7-10 days prior to surgery.   
3.2.2 Surgical procedures 
Average rat weight at surgery was 326±11g and 329±11g for the 
celiac ganglionectomy (CGx) and Sham groups, respectively. Surgery 
was performed under isoflurane anesthesia (2.5% isoflurane, Baxter 
International, Inc. in 100% O2 delivered via a nose cone at 1mL/min 
flow rate). After induction, rats were given atropine (0.2mg/kg, i.p., 
Baxter International, Inc., Deerfield, IL) for reduction of salivary and 
bronchial secretions, preoperative antibiotic prophylaxis (gentamicin, 
0.05mL, i.m., Hospira, Inc., Lake Forest, IL), preoperative pain relief 
(ketoprofen, 5mg/kg, s.c., Fort Dodge Animal Health, Inc., Overland 
Park, KS) and placed on a heated surgical bench. Surgical instruments 
were heat sterilized and all implants were cold sterilized overnight in a 
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solution of glutaraldehyde (Cidex Plus, Johnson & Johnson Services, 
Inc., New Brunswick, NJ).   
Rats were instrumented with a DSI pressure transmitter (TA11PA-
C40, Data Sciences International (DSI), Saint Paul, MN) for 
measurement of arterial pressure (AP), a 1mm Transonic flow probe 
(MC-1PRS-JS, Transonic Systems, Inc., Ithaca, NY) for measurement of 
superior mesenteric artery blood flow (MBF), a subcutaneous catheter 
for AngII delivery, and a femoral venous catheter. Implantation of the 
pressure transmitter, superior mesenteric artery flow probe and femoral 
venous catheter was performed as described previously (66). The 
subcutaneous catheter (23g, 0.02” I.D. x 0.06” O.D. Tygon Micro-Bore 
tubing S-54-HL, Saint-Gobain Performance Plastics, Corp., Akron, OH) 
used in this experiment for delivery of AngII via an external infusion 
pump was tunneled through a small dorsal skin incision. The tip of the 
catheter was positioned over the animal’s lower right flank. The catheter 
and flow probe cable were exteriorized through a skin incision over the 
scapulae, anchored to the underlying subcutaneous tissue using a 
circular surgical polyester mesh (PETKM14002, Textile Development 
Associates, Inc., Surgical Mesh Division, Brookfield, CN) which was 
implanted subcutaneously and sutured to the skin upon closure of the 
incision.  
CGx was performed in half of the rats as described by (64). After a 
midline laparotomy, the intestines were exteriorized onto a wet gauze 
and the stomach and spleen were retracted rostrally, without 
exteriorizing, to expose the great vessels and the root of the superior 
mesenteric artery. The superior mesenteric and celiac ganglia were 
removed along with the connective tissue and nerve fibers comprising 
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the celiac plexus. Care was taken to keep the lymphatic vessel coursing 
along the superior mesenteric artery and abdominal aorta intact. The 
other half of rats were subject to sham surgery in which the celiac and 
superior mesenteric ganglia were exposed, but kept intact by dissecting 
the overlying peritoneal membrane.  
Rats were given 10-14 days to recover from surgery. Ketoprofen 
(5mg/kg, s.c., Fort Dodge Animal Health, Inc., Overland Park, KS) was 
administered daily for 3 days post surgery for pain management. Fluid 
intake was monitored closely during recovery and supplemental fluid 
was given (6-8mL isotonic saline, s.c. bolus, B. Braun Medical, Inc., 
Irvine, CA) through the subcutaneous catheter as needed.  
3.2.3 Tethering and Housing 
The distal ends of the catheters and probe cable were tunneled 
though a stainless steel spring (Exacto Spring, Corp., Grafton, WI) used 
for tethering the rat to swivel. The end of the spring in contact with the 
rat was fitted with a 1” piece of Tygon tubing (3/16” I.D. x 5/16” O.D. 
Tygon S-50-HL Saint-Gobain Performance Plastics, Corp., Akron, OH) 
to cushion its contact with the skin. Unlike the previously described 
technique where the spring was affixed to the animal using a 
conventional subcutaneous button tether with the spring passing 
through the skin, the spring was allowed to sit freely over the skin. The 
catheters and cables were attached to the spring by placing a piece of 
tape over where they exited the spring. This simplified tethering 
technique, adapted from that used at Dr. Kenju Miki’s laboratory (Nara 
Women’s University), improved healing of the exit wound and improved 
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reliability of tethering compared to our previously described method 
(66).  
Instrumented rats were housed throughout the study in a standard 
box cage (Allentown, Inc., Allentown, NJ) with an electrical swivel 
(SVL6C, Kent Scientific, Corp., Torrington, CT) mounted above the 
cage for the flow probe connection. The subcutaneous catheter for AngII 
infusion was attached to a single channel hydraulic swivel (Model 
375/22PS, Instech Laboratories, Inc., Plymouth Meeting, PA) mounted 
above the electric swivel. 
3.2.4 Experimental protocol 
The experimental protocol consisted of 4 days of control followed by 
a 14 day AngII infusion period. AngII (A9525, Sigma-Aldrich, Co., 
LLC., St. Louis, MO)  was administered at a dose of 150ng/kg/min at a 
volume flow rate of 5uL/hr through the subcutaneous catheter attached 
to an external Harvard infusion pump (Model 935, Harvard Apparatus, 
South. Natick, MA). This infusion rate was chosen to match that in 
Alzet osmotic minipumps (2ML2, DURECT, Corp., Cupertino, CA) 
used in our previous study (66). Rats were given distilled water and a 
pelleted high salt diet (2.0% NaCl added rodent diet, Research Diets, 
New Brunswick, NJ) ad libitum throughout the experiment. Isotonic 
saline was infused through the subcutaneous catheter during the control 
period. The femoral venous catheter was flushed every other day with 
50U/mL heparinized saline (Sagent Pharmaceuticals, Inc., Schaumburg, 
IL). An amount of AngII infusate needed for the length of the protocol 
was prepared in isotonic saline on the first day of infusion and used 
throughout the 14days of infusion. 
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Sympathetic tone was assessed by measuring the responses of mean 
arterial pressure (MAP), heart rate (HR), and mesenteric vascular 
resistance (MVR) to acute ganglionic blockade with hexamethonium 
(20mg/kg, i.v., H0879, Sigma-Aldrich, Co., St. Louis, MO) on day 3 of 
the control period and days 1,3,5,7,10, and 13 of AngII infusion. The 
dose of hexamethonium was adjusted based on the body weight 
measured on the day of experiment.  
3.2.5 Confirmation of successful denervation 
Sympathetic denervation of the splanchnic organs following celiac 
ganglionectomy was determined post-mortem by measurement of 
norepinephrine (NE) content in the spleen. NE content was also 
measured in both kidneys to assess the effect of CGx on renal 
sympathetic innervation. Tissues were explanted on the 15th day of 
AngII infusion. Explanted tissues were rinsed in isotonic saline and 
gently blotted for removal of excess blood, stored in 1.5mL 
microcentrifuge tubes and flash frozen in liquid nitrogen. Tissues were 
stored in -80°C until analytic determination of NE content using high-
performance liquid chromatography with electrochemical detection (64). 
3.2.6 Data collection 
AP and MBF were recorded continuously throughout the experiment 
at a 500Hz sampling rate using acquisition software from DSI 
(DataQuest ART Acquisition). The acquisition hardware for AP and 
MBF has been described in detail previously (66). MAP, HR and mean 
MBF were calculated and stored every 10s using the built-in online 
analysis routine in the acquisition software. 
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3.2.7 Data analysis and Statistics 
10s interval data for MAP, HR, and mesenteric blood flow (MBF) 
was averaged over 24hrs through the 19 days of the protocol using 
analysis software from DSI (Dataquest ART Analysis) and exported to 
JMP software (version 10, SAS Institute, Inc., Cary, NC). MVR was 
calculated as MAP/MBF from the 12hr averaged values. Baseline values 
for food intake, water intake, MAP, MBF and MVR during control were 
obtained from the average value of the 4 control days. 
The acute response to ganglionic blockade was analyzed using 
LabChart Pro (ADInstruments, Dunedin, New Zealand) software after 
exporting DSI arterial pressure and blood flow waveform data to open 
source EDF file format using custom written software in C++ using 
reference code provided by DSI (ART Reader 4.0, available from DSI 
upon request). MAP, HR, MBF, and MVR were calculated from the 
pulsatile data on a beat-by-beat basis for determining the peak changes 
following ganglionic blockade. The 10min baseline value immediately 
prior to injection was subtracted from this value and used as index to 
assess changes in peripheral sympathetic tone. 
3.2.8 Statistics 
Baseline BW, food intake, water intake, MAP, MBF and MVR 
during control were compared between Sham and CGx groups by 
multiple unpaired t-tests. Between and within group differences in the 
response of the various parameters measured throughout the AngII-salt 
protocol were tested for statistical significance using repeated-measures 
analysis of variance (ANOVA) followed by a Holm-Sidak multiple 
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comparisons test using SigmaPlot (version 11, Systat Software, Inc., 
Richmond, CA)  
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3.3 Results 
Of the 28 rats used in the study, 8 were excluded from the final 
analysis due to lack or loss of superior mesenteric artery blood flow 
(SMABF) signal after flow probe implantation. The remaining 20 rats 
consisted of 10 subjected to CGx and 10 Sham treated rats. Successful 
sympathetic denervation of splanchnic organs by CGx was confirmed by 
measurement of tissue NE content in the duodenum and spleen. Results 
are shown in Figure 1 along with tissue NE content in the left kidney to 
assess the degree of renal involvement in CGx. Results are consistent 
with previously published data and confirms that CGx resulted in 
effective splanchnic sympathectomy with relative renal sparing.   
3.3.1  Effect of CGx on baseline parameters 
Shown in Table 1 are comparisons between Sham and CGx rats for 
variables measured throughout the study. There were no differences 
between groups for body weight, food or water intake. As seen in 
previous studies (42, 64, 110), CGx rats had a lower MAP and slightly 
higher HR during the baseline period. This was associated with elevated 
mesenteric blood flow and reduced mesenteric vascular resistance in 
CGx rats. 
3.3.2 Effect of CGx on the splanchnic hemodynamic 
profile of AngII-salt hypertension 
There were no appreciable differences in body weight, food intake, 
and water intake between CGx and Sham treated rats during baseline 
and throughout the 14 day AngII infusion period (Figure 2).  A 
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representative example of the arterial pressure and mesenteric blood 
flow (MBF) signals obtained over a 60-minute period in conscious freely 
moving Sham and CGx rats is shown in Figure 3 (bottom panel). 
Examination of a 3 second window from this recording period reveals 
the stability and high fidelity of these recordings. These signals were 
used to derive 24-hour averages of mean arterial pressure (MAP), MBF, 
mesenteric vascular resistance (MVR) and heart rate (HR) for both 
experimental groups.  
As shown in Figure 4, AngII infusion caused a gradual and 
continuous rise in MAP, accompanied by a rise in MVR with no change 
in MBF, in both groups. HR decreased during the first week of AngII 
infusion in both groups and appeared to stabilize at this lower level in 
Sham rats, in contrast to a gradual recovery toward baseline in CGx 
treated rats. There were no statistically significant differences in the 
changes to MAP and HR during AngII infusion between CGx and Sham 
treated rats. 
Differences in MVR between CGx and Sham treated rats were not 
statistically significant during days 1 through 8 of AngII. However, 
MVR in CGx treated rats stabilized at statistically lower values 
compared to Sham on days 9 and 11 through 14 of AngII. There was a 
corresponding, statistically significant difference in MBF between CGx 
and Sham treated rats on days 8 through 14 of AngII.  
3.3.3 Effect of CGx on responses of MAP, MVR and 
HR to acute ganglionic blockade 
The contribution of sympathetic activity to MAP, MVR and HR in 
Sham and CGx rats was assessed by measuring the response of these 
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variables to acute ganglionic blockade (see Figure 5). As we have 
previously reported (66), the depressor effect of ganglionic blockade 
gradually increased during the AngII infusion period in Sham rats in 
that the depressor response was statistically greater on days 3, 5, 7, 10 
and 13 of AngII compared to control, Surprisingly, the response was 
similar in CGx rats and there were no statistically significant differences  
between groups at any time during the protocol. 
The mesenteric vasodilatory response to ganglionic blockade tended 
to increase during AngII infusion in both Sham and CGx treated groups 
(Figure 5; middle panel). These responses were not statistically different 
from baseline however except for day 13 of AngII in CGx treated rats. 
There were no statistically significant between group differences at any 
of the tested time points. 
The bradycardic response to ganglionic blockade appeared to be 
reduced during AngII days 5 and 7 in Sham and CGx treated rats, 
respectively. This change, however, was not statistically significant. 
There were no statistically significant between group differences in the 
bradycardic response to ganglionic blockade at any of the tested time 
points. 
  
 60 
3.4 Discussion 
The aim of this study was to extend previous findings generated by 
the collaboration between our two laboratories (J.W.O and G.D.F.) and 
further test the hypothesis that the neurogenic component of AngII-salt 
hypertension is primarily mediated by an increase in neurogenic tone to 
the splanchnic vascular bed. Our previous studies have shown that 
AngII-salt hypertension is accompanied by a reduction in systemic 
vascular capacitance, which is reversible by ganglionic blockade and 
prevented by sympathectomy of the splanchnic vascular bed by CGx. 
Most importantly, CGx attenuated AngII-salt hypertension to levels 
seen in AngII-hypertensive rats fed a normal NaCl diet, a model thought 
to have a minimal neurogenic component (63). We have recently shown 
by direct continuous measurement of superior mesenteric artery blood 
flow in conscious rats that AngII-salt hypertension is accompanied by a 
sustained increase in mesenteric vascular resistance (MVR), and this 
response is acutely reversible by ganglionic blockade (66). This finding is 
consistent with our initial hypothesis, and provided a more direct index 
of splanchnic vascular hemodynamics in AngII-salt hypertensive rats. 
However, this finding does not exclude the possibility that non-
neurogenic mechanisms also contribute to increased MVR in AngII-salt 
hypertension. Therefore, the present study was designed to test the 
hypothesis that CGx would attenuate or abolish the increase in MVR 
observed during the development of AngII-salt hypertension.  
There were three main findings in this study. First, CGx chronically 
lowered baseline MVR in normotensive rats. Second, continuous AngII 
administration for 2 weeks caused a similar increase in MVR in Sham 
and CGx rats. Finally, CGx had no effect on the development of AngII-
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salt hypertension. The interpretation and significance of these findings 
are discussed below. 
3.4.1 CGx chronically decreases mesenteric vascular 
resistance and arterial pressure in normotensive rats 
The contribution of organ specific basal sympathetic tone to long-
term control of arterial pressure under normal conditions has not been 
extensively studied with the exception of the kidney. Specifically, renal 
denervation has been shown to cause a sustained reduction in arterial 
pressure in normotensive Sprague-Dawley rats (55, 57). This response is 
not due to reductions in renin release or sodium balance and has been 
hypothesized to be secondary to a chronic reduction in renal vascular 
resistance (57).  Although this remains a controversial topic (30), it has 
been shown that basal renal SNA in normal rats contributes to renal 
blood flow fluctuation during normal behavior (116). Malpas et.al. have 
shown that in rabbits, renal denervation chronically lowers renal 
vascular resistance (77, 78). More recently, a study in pigs has shown 
that catheter based radiofrequency ablation of renal nerves results in a 
sustained decrease in renal vascular resistance and increased renal blood 
flow one month post ablation, suggesting that tonic sympathetic input is 
an important contributor to basal levels of renal vascular tone (109).  
We observed in the present study that denervation of the splanchnic 
vascular bed by CGx also results in sustained hypotension, similar in 
magnitude to renal denervation (55, 57). Although similar observation of 
a chronic hypotensive effect of CGx has been reported by others (64, 
110), the mechanisms mediating this response are not clear. It has been 
suggested that the acute hypotensive effect of CGx in anesthetized 
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animals is primarily due to an increase in portal venous capacitance, 
which decreases venous return, cardiac output, and consequently arterial 
pressure (45). The mechanisms mediating the chronic hypotensive effect 
of CGx in conscious freely moving animals, however, appear to be driven 
by a different process. Total vascular capacitance, which is 
predominantly determined by splanchnic venous tone (33, 41), is similar 
in Sham and CGx rats (64). This finding suggests that either basal 
sympathetic activity to splanchnic veins is very low or adaptations occur 
to restore vascular capacitance following CGx (64). In contrast, we 
found in this study that MVR was chronically decreased in CGx rats 
suggesting that sustained vasodilatation of the splanchnic resistance 
vessels is partially responsible for the chronic hypotensive effect of CGx. 
Taken together, the studies discussed above suggest that sympathetic 
activity is an important long-term controller of basal renal and 
mesenteric vascular resistance and arterial pressure under normal 
conditions.   
3.4.2 Effect of CGx on mesenteric vascular resistance 
in AngII-salt hypertensive rats  
Although basal MVR was chronically decreased under basal 
conditions in CGx rats, the mesenteric vasoconstrictor response to AngII 
administration was similar to Sham control rats. Absolute values for 
MVR were lower in CGx compared to Sham rats on days 9 and 11-14 of 
AngII, in part because of a lower basal level compared to Sham rats. 
Despite these differences in absolute level of MVR between Sham and 
CGx rats, the final level of arterial pressure after 14 days of AngII was 
the same in both groups.  
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This unexpected finding suggests that the increase in MVR during 
AngII administration is driven by non-neurogenic mechanisms. One 
possibility is that MVR increases in response to elevated perfusion 
pressure of the splanchnic vascular bed. Such pressure sensitive 
mechanisms may include changes in the myogenic response of mesenteric 
arterioles (104), impairment of flow-mediated vasodilation (1, 103), or 
an increase in AngII receptor density on mesenteric arterioles due to 
exposure to high perfusion pressure (71) leading to an increase in direct 
AngII vasoconstrictor tone. 
Our hypothesis that increased MVR in AngII-salt rats is 
sympathetically mediated was based on our recent finding that the 
mesenteric vasodilatory response to ganglionic blockade increases 
statistically over the 14 day period of AngII administration in intact rats 
(66). We observed the same trend in Sham rats in the present study 
although it was not statistically significant. More importantly, in the 
present study, this response was the same in CGx and Sham rats. One 
explanation for this finding is that the MVR response to ganglionic 
blockade is a secondary autoregulatory response to decreased perfusion 
pressure. The mechanism mediating the MVR response to ganglionic 
blockade in CGx rats remains to be determined. Overall, these findings 
suggest that AngII mediated changes in splanchnic arteriolar 
hemodynamics assessed by measurement of superior mesenteric artery 
blood flow are predominantly mediated by non-neurogenic mechanisms. 
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3.4.3 Effect of CGx on the development of AngII-salt 
HTN: Reconciliation with previous studies 
We have previously reported that CGx attenuates AngII-salt 
hypertension (64). In the present study, however, neither the slow rising 
pressor response to AngII administration, or final level of arterial 
pressure, was affected by CGx. Furthermore, the gradual increase in the 
depressor response to ganglionic blockade over the 2 week period of 
AngII administration, an indirect indicator of “whole body” sympathetic 
tone, was unaffected by CGx.  These findings are inconsistent with the 
hypothesis that the neurogenic component of AngII-salt hypertension is 
mediated by increased sympathetic tone to the splanchnic vascular bed. 
Failure of CGx to attenuate AngII-salt hypertension occurred despite 
successful splanchnic sympathectomy, as evidenced by the baseline 
hemodynamic profile of CGx rats (i.e., decreased MAP and MVR) and 
significantly lower tissue NE content in the duodenum and spleen.  The 
response of tissue NE content in this study is similar to those reported 
by others from our group (42, 58, 64, 110).  
There are at least three explanations for this unexpected finding. 
First, differences in the method of AngII delivery between studies may 
have impacted the overall characteristics of the model.  In our previous 
studies (62, 64) AngII was delivered subcutaneously using Alzet osmotic 
minipumps. Although this method of delivery is standard for AngII-
induced rodent models, our experience with unpredictability of pump 
performance led us to switch to using an external syringe pump. This 
decision was influenced by two factors. First, since animals needed to be 
tethered for externalization of the flow probe cable, exteriorizing a 
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subcutaneous catheter was straightforward and would not complicate 
the preparation. Second, we reasoned that use of an external syringe 
pump, which was carefully calibrated and monitored daily to insure 
stable long-term delivery of AngII, would be superior to the Alzet 
minipumps.  In a recent preliminary study we discovered that, despite 
using the same volume flow rate and AngII infusate concentration as our 
previous studies, Alzet pumps result in a marked spike in plasma AngII 
on Day 3 of infusion compared to a traditional external syringe pump 
(67). The relevance of this finding is that Johnson and colleagues have 
recently reported that a brief period of AngII administration amplifies 
the hypertensive response to subsequent AngII infusion and this 
response is most likely to be neurally mediated (114). This would be 
consistent with the idea that the “spike” in plasma AngII observed with 
Alzet minipumps delivery may “prime” the neurogenic component of 
AngII-salt hypertension. Whether or not differences in the plasma AngII 
profile between these two methods of AngII administration is sufficient 
to explain the discrepancy between the present study and our previous 
reports remains to be established. 
A second explanation is that the extent of denervation affecting the 
kidney was different between this study and the previous study by King 
and colleagues (64). As expected, tissue NE content was decreased in 
CGx rats in both studies in splanchnic organs. In the current study, 
renal NE content was not affected in CGx rats indicating innervation of 
the kidneys was not affected to a significant extent. This contrasts with 
the statistically significant decrease in NE content of the left kidney in 
CGx rats in the study of King et al. (64).  Since the surgical approach 
for CGx exposes the left peritoneal cavity by exteriorizing the gut 
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content to the left surgical field, it is possible that in the study of King 
et al CGx not only removed the celiac plexus (celiac and superior 
mesenteric ganglia), but also extended to renal ganglia and possibly as 
far as the left suprarenal ganglion (101), thus affecting the innervation 
to the left kidney to a greater extent than the right. Although renal 
denervation alone did not affect AngII-salt hypertension in that study 
(64), it is conceivable that CGX resulted in denervation of the 
splanchnic vascular bed and sympathetic input to the kidneys resulting 
in an additive blood pressure lowering effect. We have recently reported 
such an additive effect of renal denervation and CGx on blood pressure 
in the Dahl-S rat model of hypertension (42).  
A third possibility is suggested by the recent hypothesis that 
sympathetically mediated release of endogenous ouabain from the 
adrenal cortex plays a role in salt sensitive hypertension by amplifying 
sympathetic input to the vasculature (8). Indeed, we came to this same 
conclusion to explain our recent studies on neural mechanisms mediating 
increased arterial pressure in rats during 48hrs of water deprivation 
(110). Although the pressor response to water deprivation is 
sympathetically driven, it is not affected by targeted sympathetic 
ablation of the kidneys, splanchnic vascular bed or hind limb (110). 
However, adrenalectomy, but not adrenal demedullation, attenuated this 
pressor response in the same time frame as chronic adrenergic receptor 
blockade. We hypothesized that neural control of adrenal cortical release 
of endogenous ouabain may be the mechanism mediating this response 
(110). Similar to the AngII-salt model (87), 48 hours of water 
deprivation is believed to drive sympathetic activity via a central 
osmotic stimulus and elevated plasma AngII levels (110). This link raises 
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the possibility that the hypotensive response of AngII-salt rats to CGx 
reported by King and Fink, but not in this study, may have been the 
result of denervation of the adrenal cortex (i.e. endogenous ouabain 
release) rather than the splanchnic vasculature per se. The possibility 
that endogenous ouabain release mediate the hemodynamic changes 
observed in this model is supported by early experiments in dogs, which 
have shown an increase in MVR, and decrease in vascular capacitance in 
response to exogenously administered ouabain (46). This interesting 
hypothesis remains to be tested.  
3.4.4 Perspectives 
Our laboratories (J.W.O. and G.D.F.) have collaborated over a 
number of years to investigate the role of regional sympathetic activity 
in the rat model of AngII-salt hypertension (64, 66, 85, 86, 87, 88, 108, 
115). To enable comparison of results between laboratories, we have 
used a standardized protocol and same sources for rats, specialized diets, 
and AngII. In addition, both laboratories have employed the same 
method of subcutaneous AngII delivery using implantable osmotic 
minipumps. Although this method is convenient, our experience is that 
it suffers from unpredictability of pump performance. In this study, 
AngII was delivered subcutaneously using an external syringe pump 
using the identical AngII infusate concentration and volume flow rate as 
our previous studies. We reasoned that this subtle difference in AngII 
delivery would not impact the model. 
 Contrary to our hypothesis, and a previous paper from our group, 
CGx had no impact on the response of MVR or arterial pressure to 
AngII administration in rats consuming a high salt diet. One possibility 
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for the difference between studies is the method of AngII administration. 
It has been shown that the mechanism and severity of AngII-induced 
hypertension is sensitive to dose and level of dietary salt intake (26, 79, 
97), and prior physiological stimuli that may transiently elevate plasma 
AngII levels (114). Another possibility is subtle differences between 
laboratories for the method of CGx and target organs affected.  
Although our study presents the challenge of reconciling results 
between two laboratories that have worked closely together using a 
standardize protocol, it also highlights the much greater challenge of 
comparing studies in the literature from different laboratories using 
differences species of study and vastly different protocols of AngII 
induced hypertension (e.g. salt diet, dose of AngII, route and method of 
AngII delivery). A continued collaboration between our laboratories to 
reconcile the effects of CGx on AngII-salt hypertension are most likely 
lead to new discoveries regarding both neural and non-neural 
mechanisms of this experimental model of hypertension. 
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3.5 Figures and Table 
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Table 3.1. Baseline parameters 
 
Baseline parameters in Sham and CGx rats during control period. 
Values for food intake, water intake, heart rate (HR), mean arterial 
pressure (MAP), mesenteric blood flow (MBF), and mesenteric vascular 
resistance (MVR) are averages of 24hr values from the 4 control days.  
(∗) denote significant (p < 0.001) between group differences.  
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Table 3.1 
 
 
  
 73 
Figure 3.1. Tissue NE content 
 
Tissue norepinephrine (NE) content in left kidney (LK), spleen (SP) 
and duodenum (DD) harvested from Sham (white bars) and CGx rats 
(black bars) one day after the 14 days of AngII infusion. Tissue NE was 
measured by HPLC. (∗) denote significant (p<0.05) between group 
differences. 
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Figure 3.1 
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Figure 3.2. Daily food/water intake, changes in body 
WT during AngII-salt hypertension 
 
Changes in body weight and daily food and water intake during 
control and AngII-salt hypertension in Sham (unfilled bar and circles) 
and CGx (filled bar and circles) rats. “C” and “A” prefixes on x-axis 
denote control and AngII days, respectively. (†) and (‡) denote 
significant within group difference compared to day 3 of control in Sham 
and CGx rats, respectively. Error bars are S.E.M. 
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Figure 3.2 
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Figure 3.3. Representative AP, MBF Waveform 
 
Representative arterial pressure (AP) and superior mesenteric artery 
blood flow (MBF) waveform data collected from Sham (left) and CGx 
(right) rats during the study. Bottom panel shows compressed waveform 
data from a 1hr period during the light cycle on control day 3. The firs 3 
seconds from this 1hr segment is shown on the top panel.    
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Figure 3.3 
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Figure 3.4. 24hr hemodynamic profile of MAP, MVR, 
MBF, and HR during AngII-salt hypertension 
 
24hr average mean arterial pressure (MAP), mesenteric vascular 
resistance (MVR), superior mesenteric artery blood flow (MBF), and 
heart rate (HR) during control and AngII-salt hypertension in Sham 
(unfilled circles) and CGx (filled circles) rats. “C” and “A” prefixes on x-
axis denote control and AngII days, respectively. (†) and (‡) denote 
significant within group difference compared to day 3 of control in Sham 
and CGx rats, respectively. (∗) denote significant (p<0.05) between 
group differences. Error bars are S.E.M. 
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Figure 3.4 
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Figure 3.5. Changes in responsiveness of HR, MAP 
and MVR to acute ganglionic blockade during AngII-
salt hypertension 
 
Peak changes in mean arterial pressure (MAP), mesenteric vascular 
resistance (MVR), and heart rate (HR) after ganglionic blockade 
(hexamethonium, 20mg/kg, i.v.). Values represent absolute differences 
from a 10min baseline immediately preceding the injection. Injections 
were performed on control day 3 and days 1, 3, 5, 7, 10, and 13 of 
AngII. Unfilled and filled bars represent responses in Sham and CGx 
rats, respectively. “C” and “A” prefixes on x-axis denote control and 
AngII days, respectively. (†) and (‡) denote significant within group 
difference compared to day 3 of control in Sham and CGx rats, 
respectively. Error bars are S.E.M. 
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Figure 3.5 
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Chapter 4 
 
Effect of chronic α1/2β1-adrenergic receptor 
blockade on the development of AngII-Salt 
Hypertension 
 
4 Chapter 4: Effect of chronic α1/2β1-adrenergic receptor blockade on 
the development of AngII-Salt Hypertension 
4 Chapter 4 
4 Chapter 4 
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Chapter Overview 
The contribution of global sympathetic pressor tone in 
angiotensin-II salt (AngII-salt) hypertension has been inferred mostly 
from repeated measurements of whole body norepinephrine (NE) 
spillover and the depressor response to acute ganglionic blockade. 
Complementary evidence using chronic sympathetic blockade has been 
lacking for the AngII-salt model in the rat. To address this issue, we 
tested the effect of chronic, global sympathetic blockade on AngII-salt 
hypertension by continuous infusion of phentolamine and atenolol, a 
non-selective α1/2 and selective β1-adrenergic receptor antagonist, 
respectively. We found that α1/2β1-adrenergic receptor blockade 
attenuates AngII-induced hypertension in rats fed a high (2%) salt 
(NaCl) diet (AngII-salt hypertension) but not those in a low (0.1%) 
NaCl diet. Global sympathetic pressor tone accounted for approximately 
27% of the total change in pressure in AngII-salt hypertensive rats, as 
estimated by the differences in pressure between chronic α1/2β1-
adrenergic receptor blocked and vehicle treated rats. In addition, 
although the salt-dependent differences in the severity of AngII-induced 
hypertension was blunted by chronic α1/2β1-adrenergic receptor blockade, 
it was not completely blocked, suggesting that an increase in peripheral 
adrenergic tone plays some role, but is not the major determinant of the 
salt dependent effects on the severity of AngII-induced hypertension. We 
conclude that global sympathetic pressor tone contributes to AngII-salt 
hypertension, but to an extent that is significantly smaller than what 
has been previously assumed by acute ganglionic blockade. 
  
 85 
4.1 Introduction 
Hypertension that results from chronic administration of AngII 
(AngII-induced hypertension) is thought to be mediated, in part, by 
neurogenic mechanisms (86, 87). Several line of evidence supports this 
neurogenic hypothesis, including a progressively higher depressor 
response to ganglionic blockade (13, 62, 66, 79), prevention of this form 
of hypertension by neonatal sympathectomy (26, 98), and attenuation of 
hypertension by chronic adrenergic blockade (76). However, other 
studies employing similar techniques have found conflicting results (65, 
83). These inconsistencies can be attributed in part, to the dependence 
of the model on the level of dietary salt intake (87). The severity of 
AngII-induced hypertension in dogs (24), rats (62, 63, 64, 66), and mice 
(22) has been shown to increase progressively with higher levels of 
dietary salt intake. In both rats, and rabbits, it has been shown that the 
depressor response to ganglionic blockade is elevated during AngII-
induced hypertension selectively in animals with a high salt intake 
(AngII-salt hypertension) (62, 64, 66, 79). Furthermore, our group has 
shown that NE spillover is elevated in high salt diet rats, but not those 
fed a normal salt diet (63). 
Although global indices of sympathetic tone were highly indicative of 
a rise in adrenergic activity and enhanced sympathetic vasomotor tone 
during AngII-salt hypertension, attempts at directly measuring increases 
in sympathetic nerve activity or identifying a critical peripheral 
sympathetic target organ has been mostly unsuccessful (85). Consistent 
with other studies in AngII-induced hypertension, it has been shown 
that renal nerves have little contribution to the rise in pressure during 
AngII-salt hypertension, both on the basis of denervation (13, 64), and 
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direct nerve recording experiments (4, 115). Direct measurement of 
lumbar sympathetic nerve activity has been shown to remain unchanged 
during AngII-salt hypertension (115), and correspondingly, hind limb 
NE spillover was shown to be unchanged (61). Preliminary results from 
our lab have shown that sympathetic input to the heart has no 
contribution to AngII-salt hypertension based on findings from cardiac 
denervation and chronic β1-adrenergic receptor (β1-AR) blockade 
experiments (52). The peripheral sympathetic target organ responsible 
for the neurogenic mechanism underlying AngII-salt hypertension was 
thought to have been finally identified when it was shown that AngII-
salt hypertension is significantly attenuated by celiac ganglionectomy 
(CGx) (64). Most recently, however, we found conflicting results 
showing that CGx does not attenuate AngII-salt hypertension (see 
results in Chapter 3).  
The expected contribution of sympathetic pressor tone on AngII-salt 
hypertension has largely been based on the magnitude drop in pressure 
following acute ganglionic blockade. Although this technique has been 
validate by our lab and others as an indicator of sympathetic pressor 
tone in the rat, repeated measures obtained under chronic experimental 
settings may not necessarily reflect the response when the sympathetic 
nervous system is inhibited in the chronic setting (23, 93). 
Complementary techniques for addressing this issues, such as continuous 
administration of adrenergic blocking agents or neonatal 
sympathectomy, have been used to investigate the sympathetic 
contribution to AngII-induced hypertension, but with mixed results as 
alluded to earlier (26, 76, 98). To our knowledge, there have been no 
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studies assessing the effect of chronic sympathetic blockade specifically 
during AngII-salt hypertension.  
The objective of this study was to reassess the contribution of global 
sympathetic pressor tone during AngII-salt hypertension by chronic 
continuous administration of phentolamine, a competitive, non-specific 
α-adrenergic antagonist, and atenolol, a   specific β1-AR antagonist. 
Phentolamine was chosen over a more selective α-adrenergic antagonist 
to account for α2-adrenergic receptor (α2-AR) mediated vasoconstrictor 
effects in veins (28). Atenolol was added to the infusate primarily to 
counteract β1-AR mediated increases in plasma renin activity (84) 
expected due to increases in plasma catecholamines following non-
selective α-adrenergic blockade (92). We compared the effect of α1/2β1-
adrenergic receptor (α1/2β1-AR) blockade during AngII-induced 
hypertension in rats fed a high (2%) salt (NaCl) diet (AngII-salt 
hypertension), which is hypothesized to be highly dependent on a 
sympathetic pressor tone, and a low (0.1%) NaCl diet, in which the 
sympathetic component is thought to be less or absent.  
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4.2 Methods 
Experiments were performed in conscious, chronically instrumented 
rats in accordance with NIH guidelines. All acute and chronic 
experimental procedures were conducted after approval and under 
supervision by the institutional animal care and use committee of the 
University of Minnesota. 
4.2.1 Animal use and care 
Male Sprague-Dawley rats from Charles River Laboratories 
(Wilmington, MA) weighing 200-225g upon transfer to our facility were 
used in this study. Upon arrival, rats were switched to a high (2%) or 
low (0.1%) salt (NaCl) diet (Research Diets, Inc., New Brunswick, NJ). 
Animals were housed 2 per cage in a 12-12hr light-dark cycled room 
(8:30/20:30 cycle). Distilled water was available ad-libidum. Animals 
were allowed to acclimate for at least 1 week prior to surgery.   
4.2.2 Surgical procedure 
Surgery was performed under isoflurane anesthesia (2.5% isoflurane 
in 100% O2 delivered via a nose cone at 1mL/min flow rate). After 
induction, rats were given atropine (0.2mg/kg, i.p., Baxter International, 
Inc., Deerfield, IL) for reduction of salivary and bronchial secretions, 
preoperative antibiotic prophylaxis (gentamicin, 0.05mL, i.m., Hospira, 
Inc., Lake Forest, IL), preoperative pain relief (ketoprofen, 5mg/kg, s.c., 
Fort Dodge Animal Health, Inc., Overland Park, KS) and placed on a 
heated surgical bench. Surgical instruments were heat sterilized and all 
implanted instruments were cold sterilized overnight in a solution of 
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glutaraldehyde (Cidex Plus, Johnson & Johnson Services, Inc., New 
Brunswick, NJ).   
The left external jugular vein was cannulated via an incision slightly 
above the clavicles along the mid-clavicular line. A custom made jugular 
venous catheter was advanced 3 cm towards the right atrium. This was 
later used for acute injections of phenylephrine to test for the efficacy of 
α1-adrenergic receptor (α1-AR) blockade. The detailed surgical procedure 
and method of fabrication of the jugular venous catheter has been 
described previously (see Appendix 1). A custom made femoral venous 
catheter was advanced into the lower abdominal vena cava through the 
left femoral vein as described previously (66). A DSI pressure 
transmitter (TA11PA-C40, Data Sciences International (DSI), Saint 
Paul, MN) was implanted intraperitoneally through a midline 
laparotomy, and its catheter was inserted into the left femoral artery for 
measurement of arterial pressure as described previously (66). Finally, a 
catheter was implanted subcutaneously, through a dorsal skin incision 
on the right upper back of the animal, which was later used for chronic 
administration of AngII using an external syringe pump (model 
935, Harvard Apparatus, South. Natick, MA) as previously described 
(see Appendix 1). 
All three catheters were exteriorized through a skin incision over the 
scapulae, anchored to the underlying subcutaneous tissue using a 
circular surgical polyester mesh (PETKM14002, Textile Development 
Associates, Inc., Surgical Mesh Division, Brookfield, CN) which was 
implanted subcutaneously and sutured to the skin upon closure of the 
incision (see Chapter 3). The exteriorized catheters were threaded 
through a stainless steel spring used for tethering the rat to a dual 
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channel hydraulic swivel (model 375/D/22, Instech Laboratories, Inc., 
Plymouth Meeting, PA) mounted above their cage. The free end of the 
subcutaneous catheter and the femoral venous catheter were each 
connected to a port on the swivel. 
Rats were given a minimum of 7 days to recover from surgery. 
Ketoprofen (5mg/kg, s.c., Fort Dodge Animal Health, Inc., Overland 
Park, KS) was administered daily for 3 days post surgery for pain 
management. The femoral and jugular venous catheters were flushed 
every 4 days with 50U/mL heparinated saline (Hospira, Inc., Lake 
Forest, IL) to maintain patency between uses.  
4.2.3 Experimental protocol 
The study consisted of two factors, dietary salt (NaCl) and drug 
treatment, each with two levels; high (2%) and low (0.1%) NaCl for 
“dietary NaCl”, and vehicle and α1/2β1-AR antagonist for “drug 
treatment”. α1/2β1-AR blockade was achieved by administration of 
phentolamine and atenolol (see below for dose). Experiments with all 
four groups were conducted in parallel. The experimental protocol 
consisted of 7 days of control followed by 14 days of AngII, and a 3 day 
recovery period. Administration of vehicle or an α1/2β1-AR antagonist 
solution was started on day 0 of control and continued throughout the 
duration of the protocol. Additionally, physiological saline (B. Braun 
Medical, Inc., Irvine, CA) was administered continuously through the 
subcutaneous catheter starting on day 0 of control to maintain patency 
until switched to AngII on the 8th day of the protocol (AngII day 0).  
Vehicle or a α1/2β1-AR antagonist solution was administered through 
the femoral venous catheter using an external syringe pump (model 975, 
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Harvard Apparatus) set to deliver the solutions at a rate of 2.13mL/day 
using a 3mL syringe (Monoject, Tyco Healthcare Group, Mansfield, 
MA). The 3mL syringe was coupled to a 0.2μm syringe filter (Acrodisc, 
Pall Corporation, Ann Arbor, MI) and connected to a dual channel 
hydraulic swivel using a 23g Tygon tubing (3/16” I.D. x 5/16” O.D. 
Tygon S-50-HL Saint-Gobain Performance Plastics, Corp., Akron, OH). 
The α1/2β1-AR antagonist was prepared fresh, daily, from stock solutions 
(see section below).  
We monitored the efficacy of α1-AR blockade in α1/2β1-AR antagonist 
treated rats by measuring the pressor response to an acute injection of 
phenylephrine (10ug/kg, i.v. via jugular venous catheter). The pressor 
response to phenylephrine was tested on day 0 of control prior to 
starting the α1/2β1-AR antagonist or vehicle infusion, days 1 and 7 of 
control, and on the last day of recovery in all experimental groups. 
Vehicle or AngII was infused through the subcutaneous catheter 
using an external syringe pump (model 935, Harvard Apparatus) 
calibrated to an infusion rate of 5uL/hr using a 1mL syringe (Monoject, 
Tyco Healthcare Group). The syringe was coupled to a port on the dual 
channel hydraulic swivel using 23g Tygon tubing. On the 8th day of the 
protocol (day 0 of AngII), the syringe containing physiological saline was 
switched to one filled with AngII infusate. The subcutaneous catheter 
was primed with AngII based on the estimated catheter dead space 
(approximately 0.2mL) prior to restarting the infusion.  
Food intake and water intake was measured daily during the 
protocol. Body weights were measured periodically, and dose 
adjustments for the α1/2β1-AR antagonist solution were made weekly on 
days 7 of control, and days 7 and 14 of AngII based on weight. Dose 
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adjustment was performed only if there was an increase in weight; 
otherwise the dose was kept unchanged. 
4.2.4 Pharmacological agents 
The α1/2β1-AR antagonist solution consisted of an aqueous mixture of 
phentolamine (methanesulfonate salt; P302560, Toronto Research 
Chemicals, Ontario, Canada) and atenolol (A-7655, Sigma-Aldrich, Co., 
LLC., St. Louis, MO) containing citric acid (C0759, Sigma-Aldrich, Co.) 
and sodium citrate (S4641, Sigma-Aldrich, Co.) as buffering agents. A 
stock solution of phentolamine was prepared in sterile water at a 
concentration of 50mg/mL. As atenolol is poorly soluble in water, a 
custom recipe was formulated to prepare a 20mg/mL stock solution. It 
was found that atenolol at the required concentration would solubilize in 
a solution of 50 parts water and 3 parts stock citrate buffer with 
vigorous sonication. The stock citrate buffer solution consisted of 5.5 
parts citric acid and 3 parts sodium citrate in sterile water (final 
concentration of approximately 0.07M citric acid and 0.026M sodium 
citrate). 
The stock solutions of phentolamine and atenolol were prepared fresh 
weekly. The phentolamine stock solution was stored at -80°C. The two 
drugs were mixed daily to prepare an infusate calculated to administer 
phentolamine at a rate of 3mg/kg/hr and atenolol at a rate of 
2mg/kg/hr. The delivery rate of atenolol was based on a previously 
published study from our lab (57, 110). The delivery rate of 
phentolamine was based on previously reported doses (7, 106) and 
further titrated during a preliminary study to result in complete 
blockade of the pressor response to phenylephrine after a one day 
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infusion of phentolamine. The resulting mixture had a pH of 6.4. The 
osmolality of the final solution was measured using an osmometer 
(model 3320, Advanced Instruments, Inc., Norwood, MA) and corrected 
to 290mOsms/kg using a 200mg/mL hypertonic saline solution. The 
vehicle solution was prepared from the stock citrate buffer diluted to the 
same concentration as the drug mixture (approximately 16.6% v/v). The 
pH was adjusted to 6.4 using sodium hydroxide, and osmolality was 
corrected as described above.  
The AngII infusate was prepared by diluting AngII (A9525, Sigma-
Aldrich) in physiological saline to result in a delivery rate of 
150ng/kg/min at an infusion rate of 5μL/hr. A working solution of 
phenylephrine  was prepared in physiological saline at a concentration of 
50μg/mL. 
4.2.5 Data collection 
Arterial pressure (AP) was collected continuously throughout the 
experiment at a 500Hz sampling rate using acquisition software from 
DSI (DataQuest ART Acquisition). The acquisition hardware has been 
described in detail previously (66). MAP, and HR were calculated and 
stored every 10s using the built-in online analysis routine in the 
acquisition software. 
4.2.6 Data analysis and Statistics 
Time dependent changes in MAP and HR was quantified using 10s 
interval data averaged over 24hrs using analysis software from DSI 
(Dataquest ART Analysis). Both original values and changes from 
baseline (ΔMAP and ΔHR) were used for analysis. Baseline MAP and 
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HR was calculated from the average of 7 days of control, and compared 
between groups by a t-test. ΔMAP and ΔHR for each animal were 
calculated by subtracting the baseline value from each data point, and 
used for determining the effect of chronic α1/2β1 receptor blockade on 
AngII-induced hypertension for each level of dietary salt. The effect of 
α1/2β1 receptor antagonist or vehicle treatment on the dietary salt 
dependent differences in the magnitude of AngII-induced hypertension 
was determined from the original MAP and HR values. Between and 
within group differences in MAP, ΔMAP, HR, and ΔHR during AngII 
infusion was tested for statistical significance by 2-way repeated-
measures ANOVA followed by a Holm-Sidak multiple comparisons test 
when appropriate.  
The pressor response to acute phenylephrine injection was analyzed 
using LabChart Pro (version 7, ADInstruments, Dunedin, New Zealand) 
and Matlab (version R2012a, Mathworks, Inc.). MAP data was 
extracted from the 500Hz signal and averaged over XXXs intervals using 
LabChart Pro. Quantification of the pressor response was carried out in 
Matlab. The average MAP from a 5 min. period immediately before the 
injection was subtracted from each trace to account for baseline MAP 
differences between vehicle and α1/2β1 receptor antagonist treated rats. 
The pressor response was quantified as an area under the curve (AUC) 
calculated from the MAP trace starting at the beginning of PE injection 
to 5min after the injection. The extent of α1 receptor blockade resulting 
from α1/2β1 receptor antagonist infusion for each animal was determined 
by calculating the AUC ratio using the AUC from the PE response prior 
to vehicle or antagonist infusion (on control day 0) as denominator. 
Between group differences in AUC and within group changes in the 
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AUC ratio were tested for statistical significance by 2-way repeated-
measures ANOVA followed by a Holm-Sidak multiple comparisons test 
when appropriate. 
Data were tabulated and graphed using JMP software (version 10, 
SAS Institute, Inc., Cary, NC). Statistical analysis was performed in 
SigmaPlot (version 11, Systat Software, Inc., Richmond, CA). All values 
are shown as mean ± S.E.M unless otherwise noted. 
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4.3 Results 
4.3.1 Effect of chronic α1/2β1-AR blockade on 24hr 
food, water intake and body weight 
Food intake was transiently lower in α1/2β1-AR antagonist treated 
rats, especially in the low salt group, as shown in Figure 4.1. In the low 
salt group, rats treated with α1/2β1-AR antagonist had lower food intake 
compared to those receiving vehicle solution during most of control 
through day 5 of AngII. After day 5 of AngII, food intake was, for the 
most part, comparable between vehicle and α1/2β1-AR antagonist treated 
rats. In the high salt group, food intake were similar between vehicle 
and α1/2β1-AR antagonist treated rats except for day 1 of control and 
days 2 and 3 of AngII.  
Water intake was for the most part unaffected by α1/2β1-AR 
blockade. Water intake in the low salt group was lower in α1/2β1-AR 
antagonist treated rats on day 1 of control, but otherwise the same as in 
vehicle treated rats throughout the protocol. In the high salt group, 
water intake was lower in α1/2β1-AR antagonist treated compared to 
vehicle treated rats on day 1 of control, and days 2 and 3 of AngII; 
corresponding to the same days that food intake was lower in the α1/2β1-
AR antagonist treated rats.  
Body weights were comparable across all 4 groups of rats until day 7 
of control (Table 4.1). From control day 7 onwards, vehicle treated rats 
in the low salt group showed greater weight gain compared to α1/2β1-AR 
antagonist treated rats fed a low salt diet. The weight gain observed in 
vehicle treated rats fed a low salt diet was also greater compared to 
those seen in vehicle treated rats fed a high salt diet. The weight 
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difference between high and low salt rats in the vehicle treated group 
was statistically significant on days 7 and 14 of AngII. There were no 
significant weight differences between the remaining three groups of rats 
at any point during the protocol. 
4.3.2 Effectiveness of α1-AR blockade during chronic 
α1/2β1-AR antagonist treatment 
 The acute injection of 10ug/kg phenylephrine during control day 
0, prior to starting the infusion of α1/2β1-AR antagonist or vehicle, 
resulted in a peak pressor response of approximately 50mmHg (Figure 
4.1). Infusion of α1/2β1-AR antagonist blocked 87% and 93% of this α1-
AR mediated pressor response after one day of treatment in high and 
low salt rats, respectively (Table 4.2). Prolonged treatment with α1/2β1-
AR antagonist resulted in a gradual loss in the efficacy of α1-AR 
blockade. This was more significant in the high salt group where the 
efficacy of α1-AR blockade dropped to 55% after 26 days of α1/2β1-AR 
antagonist treatment. This drop in the efficacy of blockade in α1/2β1-AR 
antagonist treated rats was accompanied by a 113% increase in the 
pressor response to PE in vehicle treated rats fed a high salt diet. In the 
low salt group, the efficacy of the α1-AR blockade was 83% by the end 
of the protocol. There was no statistically significant change in the 
pressor response to the PE in the vehicle treated rats as was observed in 
the high salt group. 
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4.3.3 Effect of chronic α1/2β1-AR blockade on AngII-
induced hypertension in high and low salt rats 
The effect of α1/2β1-AR blockade on AngII-induced hypertension in 
high and low salt rats was compared with their respective vehicle 
treated control after subtraction of the baseline differences in MAP and 
HR (Figure 4.2). Baseline MAP and HR was calculated from the average 
24hr MAP during the 7 day control period. The baseline MAP in the 
α1/2β1-AR antagonist treated group was 87.6±1.4 and 87.7±1.4 mmHg in 
high and low salt rats, respectively. The baseline MAP in vehicle treated 
rats was 106.3±2.1 and 102.0±1.5mmHg in high and low salt rats, 
respectively. The difference in baseline MAP between blocked versus 
vehicle treated groups was 18.7 and 14.3 mmHg in high and low salt 
rats, respectively. Baseline HR in the α1/2β1-AR antagonist treated group 
was 353.4±6.1 and 346.2±4.1 BPM in high and low salt rats, 
respectively. These HR values were lower by 76.2 and 94.0 BPM 
compared to high and low salt rats in the vehicle treated group, which 
were 429.6±5.5 and 440.2±7.6 BPM, respectively. 
In high salt rats, the initial change in MAP during the first 4 days of 
AngII was similar between α1/2β1-AR antagonist treated and vehicle 
treated groups. In high salt rats, the rise in MAP on the first day of 
AngII was 21.7±3.0mmHg and 22.0±2.4mmHg in α1/2β1-AR antagonist 
treated and vehicle treated groups, respectively. In low salt rats, the rise 
in MAP on the first day of AngII was 8.7±2.0mmHg and 9.1±2.1mmHg 
in α1/2β1-AR antagonist treated and vehicle treated groups, respectively.  
The response of HR to the initial changes in MAP during AngII 
infusion was also minimally affected by α1/2β1-AR blockade in high salt 
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rats. The peak drop from baseline HR was observed on the 4th day of 
AngII in both α1/2β1-AR antagonist treated and vehicle treated groups. 
In low salt rats, the initial and overall change in HR was more gradual 
without any notable troughs.  
α1/2β1-AR blockade blunted the AngII-induced rise in MAP, with 
respect to baseline, from days 5 to 14 of AngII in high salt rats. The 
final change in MAP from baseline, averaged over days 11-14 of AngII 
when responses appeared to have plateaued, was 42.2±1.5mmHg and 
58.2±1.5mmHg from baseline in α1/2β1-AR blockade and vehicle treated 
high salt rats, respectively. This 16mmHg difference between the two 
groups represented 27% of the total rise in MAP seen in the vehicle 
group. In contrast to these effects in high salt rats, α1/2β1-AR blockade 
in low salt rats had no effect on the level of AngII-induced rise in MAP 
from baseline.  
High salt plus vehicle treated rats had a pronounced rise in HR 
following the trough on the 4th day of AngII. Absolute HR on days 7 to 
14 of AngII in high salt plus vehicle treated rats was back to baseline 
HR despite the persistently elevated MAP. α1/2β1-AR blockade 
significantly blunted this response. In low salt rats, α1/2β1-AR blockade 
did not result in a consistent difference in the change in HR observed 
during AngII-infusion. 
4.3.4 Effect of chronic α1/2β1-AR blockade on the 
difference in MAP between high and low salt rats 
during control and AngII-salt hypertension 
There were no differences in MAP between high and low salt rats in 
the vehicle or α1/2β1-AR antagonist treated groups during control. AngII 
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infusion resulted in an immediate difference in MAP between high and 
low salt rats on day 1 of AngII. This between salt level differences in 
MAP appeared to be slowly amplified through the 14 days of AngII 
infusion in the vehicle treated group. The final between high and low 
salt group differences in MAP averaged over days 11 to 14 of AngII in 
the vehicle treated group was 36mmHg. A slowly increasing between salt 
level differences in MAP remained after α1/2β1-AR blockade. The final 
between high and low salt group differences in MAP averaged over days 
11 to 14 of AngII in the α1/2β1-AR blockade group was 21mmHg. 
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4.4 Discussion 
The increasing depressor response to acute ganglionic blockade 
observed during AngII-salt hypertension has been used as evidence 
suggesting a dominant role of the sympathetic nervous system in the 
pathogenesis of AngII-salt hypertension (62, 64, 66). This observation 
led to multiple experiments designed to identify the regional 
sympathetic pathways contributing to the neurogenic mechanism of the 
model. Many of these experiments, however, have been unsuccessful or 
inconsistent at identifying the sympathetic pathway(s) underlying the 
hypothesized neurogenic mechanism of AngII-salt hypertension. Studies 
from our lab and others have so far demonstrated, via chronic 
denervation experiments, that cardiac sympathetic nerves and renal 
sympathetic nerves do not play a significant role during AngII-salt 
hypertension (52, 64). We have also shown that lumbar sympathetic 
nerves are not activated during AngII-salt hypertension, and hence 
concluded that lumbar sympathetic nerves do not play an active role in 
AngII-salt hypertension (61, 115). Although celiac ganglionectomy was 
shown to have a significant anti-hypertensive effect during AngII-salt 
hypertension in one study (64), a follow up study in our laboratory 
showed no effect of celiac ganglionectomy (see Chapter 3). These mixed 
results have called into question whether neurogenic mechanisms are 
indeed a major component of AngII-salt hypertension as suggested by 
acute ganglionic blockade. To address this issue, we re-assessed the 
sympathetic contribution in AngII-salt hypertension by way of chronic, 
global sympathetic blockade by continuous administration of 
phentolamine and atenolol, a non-selective α1/2 and selective β1-AR 
antagonist, respectively.  
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The main finding in this study was that chronic α1/2β1-AR blockade 
attenuated AngII-salt hypertension. Despite the negative results so far 
from experiments utilizing peripheral denervation for targeted 
sympathetic blockade, this study confirms the presence of a sympathetic 
contribution to the model, and supports the results from acute 
ganglionic blockade. It also complements the results showing elevated 
norepinephrine spillover during AngII-salt hypertension (63), and 
together suggests that elevated α1/2β1-AR signaling due to enhanced 
norepinephrine release from sympathetic nerve terminals contributes to 
AngII-salt hypertension.  
Another important finding in this study was that α1/2β1-AR blockade 
attenuated AngII-induced hypertension in rats fed a high salt diet (i.e. 
AngII-salt hypertension) but not those in a low salt diet. This finding 
was also consistent with results from our prior studies using acute 
ganglionic blockade (62, 66) and further supports the idea that elevated 
dietary salt intake and circulating plasma AngII act in a synergistic 
manner to elevate peripheral sympathetic outflow during AngII-salt 
hypertension. The mechanism by which circulating AngII and dietary 
salt leads to enhanced sympathetic outflow is currently not well 
understood. We have previously proposed that the integration of the 
two signals occur centrally via circumventricular organs that ultimately 
lead to increased output from brainstem sympathetic premotor neurons 
(86, 87), but further studies are necessary to elucidate the exact 
mechanisms involved in this interaction. 
4.4.1 Mechanism of blood pressure lowering effect of 
chronic α1/2β1-AR antagonist treatment during AngII-
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salt hypertension: α versus β adrenergic receptor 
mediated effects 
Blockade of α1-AR mediated arteriolar vasoconstriction likely played 
a major role in the blood pressure lowering effect of chronic α1/2β1-AR 
antagonist  treatment during AngII-salt hypertension. Since 
phentolamine is a non-specific α-AR antagonist, its inhibitory effects on 
post-synaptic α2-AR also likely played a role in the observed effects. 
Although the cardiovascular effects of α2-AR are often associated with 
its effect presynaptically, post-synaptic α2-ARs are known to exert a 
significant vasoconstrictive effect, especially in veins (5, 91). Although 
blockade of α2-AR alone would result in peripheral sympathoactivation 
with a concomitant rise in arterial pressure, it has been shown that in 
the setting of concomitant α1-AR blockade, α2-AR antagonists have an 
additional blood pressure lowering effect (69, 74). This is thought to be 
secondary to venodilation, which would raise systemic vascular 
capacitance and lower effective circulating blood volume (28, 50, 106). It 
has been shown previously that vascular capacitance is reduced during 
AngII-salt hypertension, which appears to be sympathetically mediated 
based on its response to acute ganglionic blockade (62). Thus, reduction 
in total peripheral vascular resistance and blockade of sympathetically 
mediated changes in vascular capacitance likely contributed to the blood 
pressure lowering effect of  α1/2β1-AR antagonist treatment during 
AngII-salt hypertension. 
In addition to α receptor blockade with phentolamine, atenolol, a 
selective β1-AR antagonist, was also added to the adrenergic antagonist 
infusate in order to prevent β1 mediated renin release from 
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juxtaglomerular cells (84) in response to elevated plasma catecholamine 
levels expected from chronic α1/2-AR blockade (92). This combined use 
of α/β antagonists raises the question whether the effect seen in this 
experiment were due primarily from α1/2 or β1 receptor antagonism.  
Consistent with cardiac β1-AR blockade, the blood pressure lowering 
effect of chronic α1/2β1-AR antagonist  treatment was accompanied by 
significantly lower heart rates at baseline and during AngII infusion. In 
addition to its effect on baseline HR, β1-AR blockade in high salt rats 
significantly attenuated the rise in HR seen in vehicle treated rats 
during the second week of AngII. Thus, it is possible that the blood 
pressure lowering effect seen in AngII-salt hypertensive rats treated with  
α1/2β1-AR antagonist was partially due to suppression of this HR 
response. Although the hypotensive effect of β1-AR blockade in normal 
rats is well established, the mechanism of this effect is currently not 
fully understood. It has been shown, however, that its effect on blocking 
sympathetic input to the heart alone does not account for the blood 
pressure lowering effect of β1-AR blockade (117) in normal rats. The 
effect of β1-AR blockade on renin release could have played some role, 
but it has also been shown in renal denervated rats that this mechanism 
does not fully account for the effect on basal blood pressure either (57). 
Thus, it has been hypothesized that β1-AR blockade exerts its 
hypotensive effect by reducing central sympathetic outflow through its 
activity on central β1-AR (117).  
Although the present study cannot exclude the possibility that β1-AR 
played a major role in the blood pressure lowering of AngII-salt 
hypertensive rats, preliminary studies in our lab have so far shown that 
β1-AR blockade alone is unable to attenuate AngII-salt hypertension 
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(52). Furthermore, a study in cardiac denervated rats by stellate 
ganglionectomy has shown that interruption of sympathetic tone to the 
heart has no significant effects on the normal progression of AngII-salt 
hypertension (52).  
4.4.2 Chronic α1/2β1-AR blockade explains only a 
fraction of the total effect seen by acute ganglionic 
blockade in prior studies  
Previous studies from our lab showed an approximate 40mmHg 
increase in the peak depressor response to ganglionic blockade at 2 
weeks of AngII-salt hypertension1, which suggests that approximately 
60-80% of the total rise in pressure seen during AngII-salt hypertension 
(usually about 50-60mmHg) is sympathetically mediated (66). In 
contrast, α1/2β1-AR blockade only reduced AngII-salt hypertension by 
27%, suggesting a much smaller sympathetic contribution to the blood 
pressure rise seen in the model. Although this suggests that acute 
ganglionic blockade may have overestimated the sympathetic component 
of AngII-salt hypertension, the lower estimate in the present study were 
likely due to limitations to the method employed in this study. First, 
there was a gradual decrease in α1 receptor blockade efficacy during the 
protocol, and second, only noradrenergic mediated sympathetic effects 
on blood pressure were addressed by this study. 
The decreasing α1 blockade efficiency we observed throughout the 3 
week protocol is likely one reason by which chronic α1/2/β1-AR blockade 
                                     
1 Estimate based on peak depressor response of ~80mmHg at 2 weeks of AngII-salt 
hypertension, and ~40mmHg at baseline. 
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underestimates the underlying sympathetic contribution during AngII-
salt hypertension. Since the dosage for the α1/2β1-AR antagonist was 
adjusted for body weight every 7 days, decreased effective drug 
concentration due to changes in body weight was unlikely to have 
played any major role in this reduction in α1 receptor blockade efficacy. 
Increases in α1-AR expression have been shown to occur in rats after 
chronic treatment with prazosin (119), hence changes in α1-AR 
expression level in response to chronic phentolamine treatment likely 
contributed to the increased pressor response to phenylephrine (i.e. the 
decrease in α1-AR blockade efficacy). Interestingly, the development of 
tolerance was more pronounced in rats treated with a high salt 
compared to low salt rats. In addition, a 113% increase in the pressor 
response to acute phenylephrine injection was seen in vehicle treated 
rats fed a high salt diet, suggesting that there is an underlying increase 
in phenylephrine sensitivity specifically in high salt rats treated with 
AngII. This could also explain the decrease in α1-AR blockade efficacy in 
high salt rats treated with phentolamine. The mechanism and precise 
time course of the change in phenylephrine sensitivity, presumably 
secondary to an increase in α1-AR expression, and whether these changes 
occur during AngII-salt hypertension remains to be addressed in a future 
study.  
Another possible explanation why chronic α1/2β1-AR blockade may 
underestimate the total sympathetic contribution to AngII-salt 
hypertension is that it does not account for the post junctional actions 
of other sympathetic cotransmitters, specifically, ATP and NPY (89). It 
has been shown, however, that ATP mediated vasoconstriction via P2X1 
receptor is attenuated in isolated renal afferent arterioles from rats made 
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hypertensive by AngII-infusion and fed an 8% NaCl diet (54), suggesting 
that P2X1 mediated vasoconstriction may not play a significant role in 
the sympathetic component of AngII-salt hypertension. On the other 
hand, multiple studies have shown increases in tissue and plasma levels 
of NPY as well as elevated vascular responsiveness to NPY in various 
animal models of hypertension (112). Although results from studies 
looking at the effect of pharmacological blockade of Y1 receptors have so 
far been negative in the SHR (120) or mixed in Goldblatt hypertensive 
rats (80, 96), it may be possible that NPY signaling is elevated in AngII-
salt hypertension. Future studies could address whether Y1 receptor 
mediated vasoconstriction account for the greater fall in pressure seen 
by acute ganglionic blockade in AngII-salt hypertensive rats, compared 
to blood pressure lowering effect of chronic α1/2β1-AR blockade alone. 
4.4.3 The salt sensitive component of AngII-salt 
hypertension is only partially mediated by α1/2β1-AR 
dependent neurogenic mechanisms 
Salt sensitivity of MAP during chronic administration of AngII has 
been thought to be primarily due to inappropriately high levels of SNA 
for a given level of salt intake (10, 12). Consistent with this idea, α1/2β1-
AR antagonist treatment reduced the incremental difference in pressure 
between high and low salt rats after 2 weeks of AngII infusion (i.e. the 
salt sensitivity of AngII-induced hypertension). However, chronic α1/2β1-
AR antagonist treatment did not eliminate the salt-sensitivity of AngII-
induced hypertension, suggesting that a significant portion is driven by 
non-α1/2β1-AR mediated mechanisms. As discussed previously, the 
remaining salt-sensitive component of pressure in AngII-infused rats 
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after α1/2β1-AR antagonist treatment group could still have a neurogenic 
component that is non-adrenergic. There are, however, non-neurogenic 
mechanisms that likely contribute to the remaining salt-sensitivity. 
These salt-dependent non-neurogenic mechanisms include, but are not 
limited to, AngII mediated changes in renal diuretic/natriuretic function 
(25, 72), high-salt diet mediated changes in vascular reactivity to 
circulating AngII (27), and changes in the pressor effects of other 
circulating hormones, such as endothelin and its actions on ET-A 
receptors (2). 
4.4.4 Summary and Perspectives 
This study confirms the role of sympathetic mechanisms, specifically, 
a combined α1/2β1-AR mediated mechanisms, to the hypertension 
resulting from chronic AngII infusion, and its selective effect in rats fed 
a high NaCl diet. In Figure 4.5, a schematized plot of AngII-induced 
hypertension in high and low salt rats summarizes our main findings. A 
question that remains unanswered is whether any specific regional 
sympathetic pathway contributes to the observed effect.  The 
ineffectiveness of peripheral sympathectomy approaches at recapitulating 
the findings from this and other studies utilizing global sympathetic 
blockade, so far, suggests that targets other than cardiac, renal, 
splanchnic and skeletal muscle vascular beds are involved in the 
neurogenic mechanism of AngII-salt hypertension. One possibility, based 
on similar findings by Veitenheimer et.al. in the 48hr water deprivation 
model of acute neurogenic hypertension (110), is the adrenal gland, and 
the role of adrenal cortical hormones in mediating global increases in 
sympathetic nervous system activity. An alternative possibility, 
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proposed in the same study by Veitenheimer et.al., however, is that the 
sympathetic nervous system is activated in these settings to maintain a 
certain arterial pressure set point, and is able to adapt to compensate 
for a loss of sympathetic activity to any single vascular bed. Thus in this 
latter scenario, only global sympathetic blockade would be able to fully 
block the neurogenic component of the hypertensive response. Further 
studies are needed to test whether any of these possibilities hold true in 
the AngII-salt model of hypertension. 
Although it has been suggested that the mechanism of AngII-induced 
hypertension, in the later phases, is almost exclusively neurogenic (6), 
we found that the overall contribution of sympathetic tone to the final 
level of pressure at 2 weeks of AngII-salt hypertension is considerably 
smaller than estimated by ganglionic blockade when tested using chronic 
α1/2β1-AR blockade. The discrepancy in results obtained from ganglionic 
blockade and chronic α1/2β1-AR blockade may have been due to the 
effect of tolerance to chronic pharmacologic treatment, and non-
adrenergic sympathetic cotransmitters that were not tested in this 
study. However, our results also suggest that a significant component of 
hypertension during the later phase of AngII infusion may be mediated 
by non-neurogenic mechanisms, and that data from ganglionic blockade 
experiments may have overestimated the overall neurogenic contribution 
to the model.  
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4.5 Figures and Table 
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Figure 4.1. 24hr Food and Water Intake in α1/2β1-AR 
antagonist treated and vehicle treated rats 
 
24hr food and water intake in α1/2β1-AR antagonist treated (light 
grey) and vehicle treated rats (black) fed a high (2%) or low (0.1%) salt 
(NaCl) diet. Measurements were carried out once a day during the light 
phase of the dark-light cycle. Values represent group mean±S.E.M. (†) 
and (‡) denote significant (p<0.05) within group difference compared to 
day 7 of control in vehicle and  α1/2β1-adrenergic antagonist treated rats, 
respectively. (∗) denote significant (p<0.05) between group differences n 
= 7 for both α1/2β1-AR antagonist treated and vehicle treated groups fed 
a 2% NaCl diet; n = 6 for the α1/2β1-AR antagonist treated group fed a 
0.1% NaCl diet; n = 8 for the vehicle treated group fed a 0.1% NaCl 
diet. 
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Figure 4.1 
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Table 4.1. Change in body weight in α1/2β1-AR 
antagonist treated and vehicle treated rats 
 
Body weight prior to initial surgery, beginning of protocol, and 
weekly changes during chronic α1/2β1-AR antagonist or vehicle 
treatment, and 2 weeks of AngII administration. Weights are reported in 
grams. Values represent mean±S.E.M. n = 7 for both α1/2β1-AR 
antagonist treated and vehicle treated groups fed a 2% NaCl diet; n = 6 
for the α1/2β1-AR antagonist treated group fed a 0.1% NaCl diet; n = 8 
for the vehicle treated group fed a 0.1% NaCl diet. 
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Table 4.1 
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Figure 4.2. Blood pressure response to acute 
phenylephrine injection in α1/2β1-AR antagonist 
treated and vehicle treated rats 
 
The degree of α1-AR blockade in rats chronically treated with an 
α1/2β1-AR antagonist was tested on days 1 and 7 of control and 3rd day 
after cessation of AngII infusion (Recovery; “R”) by measuring the 
arterial pressure response to an acute injection of phenylephrine (PE; 10 
μg/kg, i.v.). The tracing shown under “C00” was obtained prior to 
starting the vehicle or α1/2β1-AR antagonist infusion. The tracings show 
the group averaged change in arterial pressure in response to 
phenylephrine in vehicle (light grey) and α1/2β1-AR antagonist treated 
(black) rats fed a 2% (top panel) or 0.1% NaCl (bottom panel) diet. The 
shaded areas represent the S.E.M. The baseline arterial pressure 
calculated from the average of the 5min period immediately preceding 
the PE injection was subtracted from each tracing to account for 
differences in MAP between vehicle and α1/2β1-AR antagonist treated 
rats. n = 7 for both α1/2β1-AR antagonist treated and vehicle treated 
groups fed a 2% NaCl diet; n = 6 for the α1/2β1-AR antagonist treated 
group fed a 0.1% NaCl diet; n = 8 for the vehicle treated group fed a 
0.1% NaCl diet. 
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Figure 4.2 
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Table 4.2. Level of α1-AR blockade during chronic 
α1/2β1-AR antagonist treatment 
 
The degree of α1-AR blockade in rats chronically treated with an 
α1/2β1-AR antagonist was tested on days 1 and 7 of control and 3rd day 
after cessation of AngII infusion (Recovery; “R”) by measuring the 
arterial pressure response to an acute injection of phenylephrine (PE; 10 
μg/kg, i.v.). The degree of α1-AR blockade was quantified by calculating 
the area under the curve (AUC) from the arterial pressure response 
tracing during the first 5 min after injection of PE. The baseline arterial 
pressure calculated from the average of the 5min period immediately 
preceding the PE injection was subtracted from each tracing prior to 
calculating the AUC. The values in parenthesis represent the AUC as a 
fraction of the PE response obtained prior to vehicle or α1/2β1-AR 
antagonist infusion (“C00”). (†) and (‡) denote significant (p<0.05) 
within group difference compared to baseline in vehicle and α1/2β1-AR 
antagonist treated rats, respectively. (∗) denote significant (p<0.05) 
between group differences within each dietary salt level. Values are 
reported in arbitrary units (a.u.), and represent mean±S.E.M. n = 7 for 
both α1/2β1-AR antagonist treated and vehicle treated groups fed a 2% 
NaCl diet; n = 6 for the α1/2β1-AR antagonist treated group fed a 0.1% 
NaCl diet; n = 8 for the vehicle treated group fed a 0.1% NaCl diet. 
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Table 4.2 
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Figure 4.3. Effect of α1/2β1-AR blockade on MAP and 
HR during AngII-induced hypertension in rats fed a 
2% or 0.1% NaCl diet 
 
24hr average mean arterial pressure (MAP), and heart rate (HR) 
during control and 2 weeks of AngII-infusion followed by 3 days of 
recovery in vehicle (filled circles, black line) and α1/2β1-adrenergic 
antagonist treated (unfilled circles, grey line) rats. Data for rats fed a 
low (0.1%) salt (NaCl) diet are plotted on the left panel. Right panel 
shows data for rats fed a high (2%) NaCl diet. Values are shown after 
baseline subtraction. “C”, “A”, and “R” prefixes on x-axis denote control, 
AngII days, and recovery, respectively. (†) and (‡) denote significant 
(p<0.05) within group difference compared to baseline in vehicle and  
α1/2β1-adrenergic antagonist treated rats, respectively. (∗) denote 
significant (p<0.05) between group differences. Values are mean±S.E.M. 
n = 7 for both α1/2β1-AR antagonist treated and vehicle treated groups 
fed a 2% NaCl diet; n = 6 for the α1/2β1-AR antagonist treated group 
fed a 0.1% NaCl diet; n = 8 for the vehicle treated group fed a 0.1% 
NaCl diet. 
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Figure 4.3 
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Figure 4.4. Effect of dietary salt on MAP and HR 
during AngII-induced hypertension in α1/2β1-AR 
antagonist treated and vehicle treated rats 
 
24hr average mean arterial pressure (MAP), and heart rate (HR) 
during control and 2 weeks of AngII-infusion followed by 3 days of 
recovery in rats fed a high (2%) salt (NaCl; black circles, black line) or 
low (0.1%) NaCl diet (grey circles, grey line). Data for α1/2β1-AR 
antagonist treated rats are plotted on the left panel. Right panel shows 
data for vehicle treated rats. “C”, “A”, and “R” prefixes on x-axis denote 
control, AngII days, and recovery, respectively. (∗) denote significant 
(p<0.05) between 2% NaCl and 0.1% NaCl group differences. Values are 
mean±S.E.M. n = 7 for both α1/2β1-AR antagonist treated and vehicle 
treated groups fed a 2% NaCl diet; n = 6 for the α1/2β1-AR antagonist 
treated group fed a 0.1% NaCl diet; n = 8 for the vehicle treated group 
fed a 0.1% NaCl diet. 
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Figure 4.4 
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Figure 4.5. Estimated time course and magnitude of 
the neurogenic component of AngII-salt hypertension 
 
Summary of main findings from this study depicted as schematized 
blood pressure response during AngII-salt hypertension. The neurogenic 
component of AngII-salt hypertension at 2 weeks is estimated at 
approximately 27% (rounded to 30%), and appears to be activated in a 
delayed fashion, approximately 4-5 days after AngII-infusion. At least 
40% of the blood pressure response in AngII-salt hypertension is non-
neurogenic. The mechanism responsible for the remaining 30% of AngII-
salt hypertension is likely mediated by salt-sensitive non-neurogenic 
mechanisms, or possibly other sympathetic mechanisms mediated by 
non-adrenergic cotransmitters. 
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Figure 4.5 
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Chapter 5 
 
Conclusion 
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The aim of this thesis was to determine whether changes in 
sympathetic vasomotor tone to the splanchnic vascular bed was a 
contributing mechanism to the neurogenic component of AngII-salt 
hypertension. The question to be answered was: “Is there evidence for 
regional hemodynamic changes that support the role of a targeted 
increase in sympathetic vasomotor tone to the splanchnic vascular bed?” 
Based on prior findings (62, 64, 76) , and then available anatomical 
basis for sympathetic innervation of splanchnic arteries and veins (53), 
we hypothesized that the neurogenic mechanism contributing to AngII-
salt hypertension was mediated by an increase in sympathetic vasomotor 
tone to both arteries and veins, causing a rise in total peripheral 
resistance and a reduction in vascular capacitance (40, 86). If true, the 
hypothesis would predict that there would be measurable changes in 
mesenteric vascular resistance, a variable that could be measured in 
conscious rats by measuring local blood flow at the superior mesenteric 
artery. Therefore, studies in this thesis were conducted using a technique 
developed for measuring superior mesenteric artery blood flow 
continuously, in conscious, freely moving tethered rats. The main 
findings of this thesis, along with results from2 supporting studies are 
summarized below. 
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5.1 Summary of main findings 
5.1.1 The sustained increase in splanchnic vascular 
resistance observed during AngII-salt hypertension is 
not mediated by an increase in sympathetic 
vasomotor tone (Chapters 2 & 3) 
In Chapter 2, I found that AngII-salt hypertension, but not AngII-
induced hypertension in low salt rats was associated with a sustained 
rise in mesenteric vascular resistance (MVR). Furthermore, the rise in 
MVR observed in AngII-salt hypertensive rats was also associated with 
a gradually increasing vasodilatory response to acute ganglionic 
blockade. These two evidences were consistent with the predicted 
hemodynamic changes and responsiveness to ganglionic blockade based 
on the original hypothesis. However, the responsiveness of MVR to 
ganglionic blockade alone was not conclusive evidence that the rise in 
MVR was due to increases in sympathetic vasomotor tone. An indirect 
mechanism involving withdrawal of myogenic tone in response to the 
depressor response to ganglionic blockade was equally likely. The study 
in Chapter 3 was designed to directly address the limitation in Chapter 
2 by measuring changes in mesenteric vascular resistance in rats with 
intact or devoid of sympathetic innervation to the splanchnic vascular 
bed. This was achieved by surgical stripping of the celiac-superior 
mesenteric ganglion plexus (celiac ganglionectomy; CGx) as had been 
previously described (64). 
Results from Chapter 3 showed that increases in MVR during AngII-
salt hypertension occurred in both CGx and Sham rats, suggesting that 
the rise in MVR was not dependent on an intact sympathetic 
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innervation to the splanchnic vascular bed. Another findings in this 
study was that the trend for a gradually increasing vasodilatory response 
to ganglionic blockade was present in both CGx and the surgical sham 
group, suggesting that the vasodilatory response to ganglionic blockade 
was not an index of sympathetic vasomotor tone in the splanchnic 
vascular bed.  
The findings from the above two studies leads to a conclusion that: 
“The sustained increase in splanchnic vascular resistance observed 
during AngII-salt hypertension is not mediated by an increase in 
sympathetic vasomotor tone.” 
5.1.2 Celiac ganglionectomy does not attenuate AngII-
salt hypertension (Chapter 3) 
Another major unexpected finding from the study in Chapter 3 was 
that CGx did not attenuate AngII-salt hypertension as previously 
reported (64). One likely explanation for the discrepant findings is the 
possibility for a difference in the extent of organ involvement of CGx 
between the study in this thesis and that in the previous work. As was 
shown by tissue norepinephrine (NE) content measurements, the renal 
involvement of CGx in the previous work was greater compared to CGx 
performed in the study presented in this thesis and works by others in 
our laboratory (42, 110) . The interpretation and possible mechanisms 
for the discrepant finding is revisited in a section below. 
5.1.3 Chronic α1/2β1-adrenergic receptor shows a 
much smaller role for sympathetic pressor tone during 
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AngII-salt hypertension than predicted by acute 
ganglionic blockade (Chapter 4) 
The combined evidence from renal denervation (no effect) (64), renal 
sympathetic nerve recording (decreased) (115), lumbar sympathetic 
nerve recording (unchanged) (115), hind limb norepinephrine spillover 
(unchanged) (61), stellate ganglionectomy (no effect) (52), chronic β1-
adrenergic receptor blockade (no effect) (52) and the inconsistent 
findings with celiac ganglionectomy from Chapter 3, raised the question 
whether a sympathetic pressor tone had a significant contribution in 
AngII-salt hypertension. Although the role for a sympathetic pressor 
tone had been assessed by acute ganglionic blockade, thus far, no 
chronic peripheral sympathoinhibitory intervention had shown a role for 
the importance of sympathetic pressor tone to any particular vascular 
bed in the development and maintenance of our model of AngII-salt 
hypertension. In Chapter 4, I reassessed the role of global sympathetic 
pressor tone in the development of AngII-salt hypertension by means of 
a chronic infusion of a combined α1/2β1-adrenergic receptor antagonist 
(Phentolamine and Atenolol). I found that α1/2β1-adrenergic receptor 
mediated mechanisms contribute approximately 27% of the final level of 
pressure in AngII-salt hypertensive rats, far less than what could be 
inferred from acute ganglionic blockade studies (62, 66). 
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5.1.4 AngII-salt hypertension generated by Alzet 
osmotic minipumps can spontaneously lose its 
hypertensive phenotype due to pump dependent 
mechanisms  (Appendix 1) 
In addition to the findings discussed above, one important issue 
surfaced at the conclusion of the studies described in Chapter 2. Almost 
half of the rats subjected to the AngII-salt hypertension protocol failed 
to develop a sustained hypertension after implantation of the Alzet 
pump. This response was unpredictable, uncorrelated to predicted pump 
infusion rate (based on post-explantation infusate volume), and equally 
affected rats fed a high or a low salt diet. The spontaneous drops in 
pressure in a subset of rats was problematic because it would have made 
results in studies testing blood pressure lowering treatments difficult to 
interpret. Based on preliminary findings from our laboratory showing 
good repeatability of AngII-salt hypertension using a recently introduced 
implantable mechanical pump (iPrecio) (107), we hypothesized that the 
problems observed with Alzet rats were due to failure of Alzet pumps to 
maintain a constant level of plasma AngII, which would not be observed 
in mechanical infusion devices such as iPrecio or external syringe pumps.  
A study was conducted to compare changes in mean arterial pressure 
and plasma AngII during AngII-salt hypertension generated by Alzet, 
iPrecio, or an external syringe pump (Harvard). This study is presented 
in Appendix 1, and showed that AngII-salt hypertension was generated 
more consistently using mechanical infusion devices (both iPrecio and 
Harvard pumps) compared to Alzet osmotic minipumps. Following these 
findings, AngII-salt hypertension in Chapters 3 and 4 were generated 
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using an external infusion pump connected to a subcutaneously 
implanted catheter. Unlike our original hypothesis, however, we did not 
find that differences in the arterial pressure profile observed between 
pumps were correlated with significant differences in plasma AngII 
levels. Thus, further studies may be needed to address the pump 
dependent differences in the arterial pressure response during AngII-salt 
hypertension. 
5.2 Implications of combined findings 
5.2.1 The neurogenic mechanism of AngII-salt 
hypertension is mediated by a sympathetic drive 
outside of the splanchnic vascular bed  
The study by our group (64) that formed the basis for our initial 
hypothesis  (86) suggested that sympathetic vasomotor tone to the 
splanchnic vascular bed was elevated by combining a measure of global 
index of venous tone with a surgical technique that, among other 
splanchnic organs, removed the sympathetic innervation to the 
splanchnic vascular bed. The results from Chapters 2 & 3, however, 
suggest that direct sympathetic innervation to the splanchnic 
vasculature is not necessary for the increases in splanchnic vasomotor 
tone, and that the increases can be mediated solely by non-neurogenic 
mechanisms. Although peripheral denervation techniques and both 
direct and indirect assessment of sympathetic tone to other peripheral 
vascular beds, combined with the negative findings from Chapter 3 
suggest that peripheral sympathetic tone may not be a significant 
contributor to AngII-salt hypertension, global indices of sympathetic 
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tone, combined with results from Chapter 4 suggest that peripheral 
sympathetic activity is enhanced and contribute partially to the overall 
level of pressure in the model.  
How can these apparently discrepant findings be reconciled? As 
previously discussed, there were slight differences in the tissue NE 
content profile of CGx treated rats from the study presented in this 
thesis and the prior study, which suggests the possibility that CGx on 
the prior study was more extensive, involving extrinsic innervations to 
the kidney from renal ganglia along rostral segments of the various 
branches of the renal nerve, as well as from the suprarenal ganglion. 
Thus, it may be possible that the hypotensive response observed in the 
previous work was a result from unintended damages to the 
aforementioned structures, creating a condition where renal and 
splanchnic organs were dually denervated. This dual denervation has 
been shown to have more than an additive hypotensive effect by a study 
in Dahl-S rats (42). However, in this study, both RDNx and CGx were 
individually shown to attenuate hypertension in Dahl-S rats, making 
this an unlikely explanation in the AngII-salt model.  
Another organ that could have been affected by a more extensive 
CGx, which could provide a unifying hypothesis to the overall findings, 
would be the adrenal cortex (see Figure 5.1), if damages extended to the 
suprarenal ganglia. This possibility is suggested by the known 
anatomical innervation of the adrenal cortex from postganglionic 
neurons in the suprarenal ganglia (34), and a recent hypothesis that 
sympathetically mediated release of endogenous ouabain from the 
adrenal cortex plays a role in salt sensitive hypertension by both direct 
and indirect vasoconstrictor actions on the peripheral vasculature (8). 
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Findings from a related study in our lab, the pressor response to 48hr 
water deprivation (110), also supports this possibility as discussed in 
Chapter 2. Future studies in the AngII-salt model employing 
adrenalectomy and splanchnicectomy of the adrenal cortex will likely 
shed light to the current outstanding questions.   
5.2.2 The method for generating AngII-induced 
hypertension by the subcutaneous route must be 
reconsidered for better reproducibility between and 
within laboratories 
Although the AngII-induced model of hypertension generated by 
peripheral administration of AngII is a convenient model of experimental 
hypertension, it suffers from one glaring weakness: between and within 
laboratory and experimenter variability in the resulting blood pressure 
phenotype. The prevailing level of dietary salt and dose of AngII 
administration are two known factors that can contribute to this 
variability. It has also been speculated whether the model generated by 
peripheral administration using intravenous or subcutaneous routes are 
comparable models on the basis of the 10-20 fold differences in the dose 
used to generate the model (15). My experience with the AngII-salt 
model of hypertension using subcutaneously implanted osmotic 
minipumps and results from Appendix 1 suggests that the osmotic 
minipumps may be another source of variability to the model. These 
sources of variability make it difficult to compare results between 
studies and deter progress in uncovering the neurogenic basis of AngII-
induced hypertension, a model based largely on a study by Dickinson 
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and Lawrence reported 50 years ago (31). Future investigations may 
benefit by adopting mechanical infusion devices for generating AngII-
induced hypertension.  
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5.3 Figures and Table 
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Figure 5.1. Revised Central Hypothesis 
 
Diagram depicting the possible role of the adrenal gland in the 
neurogenic mechanism of AngII-salt hypertension. One possible 
explanation for the discrepancy between the previously reported blood 
pressure lowering effect of celiac ganglionectomy from the one presented 
in this thesis is that there were differences in the extent of organ 
denervation resulting from the surgical ganglionectomy. Norepinephrine 
spillover data from the kidneys suggest that nerve pathways rostral to 
the celiac-superior mesenteric ganglia were affected in the prior study. A 
rostral structure other than the renal nerve that could have been 
affected is the suprarenal ganglion, which contains sympathetic post-
ganglionic neurons that modulate adrenal cortical activity. Recent 
studies have highlighted the role of adrenal cortical hormones, with a 
focus on endogenous ouabain, in the pathogenesis of other neurogenic, 
salt-sensitive models of hypertension. We propose the possibility that 
the neurogenic mechanism of AngII-salt hypertension may involve 
increases in sympathetic input to the adrenal cortex leading to increased 
release of adrenal cortical hormones that may in turn act directly on 
cardiovascular end-organs, or modulate the sympathetic control of these 
organs which ultimately may lead to a sustained increase in blood 
pressure. Further studies are needed to test this hypothesis. 
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Figure 5.1 
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Chapter Overview 
Angiotensin II (AngII) induced hypertension is a commonly 
studied model of experimental hypertension, particularly in rodents, and 
is often generated by subcutaneous delivery of AngII using Alzet osmotic 
minipumps chronically implanted under the skin. We have observed 
that, in a subset of animals subjected to this protocol, mean arterial 
pressure (MAP) begins to decline gradually starting the second week of 
AngII-infusion, resulting in a blunting of the slow-pressor response and 
reduced final MAP. We hypothesized that this variability in the slow-
pressor response to AngII was mainly due to factors unique to Alzet 
pumps. To test this, we compared the pressure profile and changes in 
plasma AngII levels during AngII-salt hypertension generated using 
Alzet, iPrecio implantable pumps, or a Harvard external infusion pump. 
At the end of 14 days of AngII, MAP was highest in iPrecio 
(156±3mmHg), followed by Harvard (140±3mmHg) and Alzet 
(122±3mmHg) groups. The rate of the slow-pressor response, measured 
as daily increases in pressure averaged over days 2 to 14 of AngII, was 
similar between iPrecio and Harvard (2.7±0.4 and 2.2±0.4 mmHg/day) 
groups, but was significantly blunted in the Alzet (0.4±0.4 mmHg/day) 
group due to a gradual decline in MAP in a subset of rats. We also 
found differences in the temporal profile of plasma AngII between 
infusion groups. We conclude that the gradual decline in MAP observed 
in a subset of rats during AngII-infusion using Alzet pumps is mainly 
due to pump dependent factors when applied in this particular context. 
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6.1 Introduction 
 Angiotensin II (AngII) induced hypertension is a commonly 
studied model of experimental hypertension, particularly in rodents. 
This popularity has been fueled by the prominent role that AngII plays 
in cardiovascular homeostasis and various disease states such as 
hypertension and heart failure. Additionally, the relative ease of 
generating hypertension in normal animals with a defined time of onset 
(allowing for a within group experimental design), without additional 
manipulations such as removal of a kidney and provision of salt in the 
drinking water that is often required in other models, have made it an 
attractive model. The AngII-induced model also involves multiple 
mechanisms spanning various research disciplines including autonomic 
neuroscience, nephrology, vascular biology and immunology. As a 
consequence, the AngII-induced model is widely used employing multiple 
species (e.g., mice (121), rats (64, 66), dogs (75), rabbits (79) and sheep 
(19)), routes of administration (e.g. intravenous (111), intraperitoneal 
(98), subcutaneous (64, 66), and intracerebroventricular (14)), and 
dosages (15).  
 In particular, the subcutaneous infusion model of AngII-induced 
hypertension in rodents (mice and rats) has been a popular model over 
the last two to three decades. This is likely due to the development of 
implantable osmotic minipumps (Alzet) that allow easy delivery of 
AngII without requiring a tether for connection of infusion tubing to an 
external infusion pump. Moreover, subcutaneous infusion in these species 
does not require additional surgeries to gain access to the circulation, 
the intracerebroventricular space or intraperitoneal cavity. The dose of 
AngII required to generate hypertension via the subcutaneous route is 
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usually ~10 fold that required for the model generated via the 
intravenous route (15). The reported dose for rats in the literature 
ranges from 50-500ng/kg/min, with a commonly used dose between 100-
200ng/kg/min (15). The typical duration of AngII administration is 2 
weeks (64, 66). The hypertensive response to chronic AngII 
administration is often characterized by a gradual rise in pressure 
commonly referred to as a “slow-pressor” response or the “auto-
potentiating” effect of chronic AngII administration. The severity of the 
“slow-pressor” response and final blood pressure during chronic AngII 
administration is dependent both on the dose of AngII and impending 
level of dietary salt intake (87). 
 Our laboratory has been studying the neurogenic mechanisms of 
AngII-induced hypertension in rats fed a high salt diet (2% NaCl) using 
Alzet minipumps as the primary method of subcutaneous AngII 
administration (150ng/kg/min for 2 weeks) (64, 66, 88, 115). It has been 
our experience that the model generated using this method occasionally 
fails to demonstrate the slow-pressor effect and sustained rise in pressure 
that is characteristic of the model. As shown in Figure 6.1, we have 
found that in a subset of animals subjected to the AngII-salt protocol 
pressure begins to decline gradually starting the second week of AngII-
infusion, resulting in a blunting of the slow-pressor response and reduced 
final blood pressure (labeled as “non-responders”). There have been no 
distinguishable physical signs between rats that showed the normal 
progression in pressure versus those that displayed the latter response, 
making this an unpredictable response. This variable response has been 
echoed by multiple other researchers (personal communications) 
conducting similar studies in mice and rats.  
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 There are at least three explanations for the “non-responder” 
profile including; 1) failure of the pump to maintain a constant flow rate 
over the 14 day protocol, 2) degradation of AngII within the pump, or 
3) failure of rats to respond to AngII (i.e. a true physiological non-
responder).  For the present study we focused our attention on pump 
performance as a contributing factor.  
Until recently, the only implantable pump for rodents was the Alzet 
osmotic minipump (DURECT, Corp., Cupertino, CA). However, another 
pump has recently become available; the iPrecio implantable pump 
(Primetech, Corp., Tokyo, Japan). Unlike Alzet pumps, iPrecio pumps 
are miniaturized mechanical pumps that expel fluid from a reservoir 
using a motorized peristaltic rotor that is precisely controlled by an 
embedded microcontroller (107). A recent report has shown that slight 
differences exist in the temporal profile of the pressor response to AngII 
infusion using Alzet versus iPrecio implantable minipumps (107). 
Although both Alzet and iPrecio rats displayed a slow-pressor response 
to chronic 14 days of AngII, and the final level of pressure was 
comparable between the two groups, the initial rise in pressure was 
slightly blunted in the Alzet rats compared to iPrecio rats (107). This 
suggested the possibility that characteristics inherent to the Alzet pump 
could play a role in the unpredictable responses described above.  
In the previously reported study, no other variables, such as plasma 
AngII concentration, were measured to provide a possible explanation 
for the observed differences in the profile of AngII-induced hypertension 
between Alzet and iPrecio groups. In addition, observed differences were 
based on a comparison with a device that has just recently been 
introduced to the scientific community, making it difficult to assess 
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whether these results could be generalized when compared to other 
traditional methods of delivery such as an external infusion pump. 
Furthermore, the reported study was based on a protocol using an 
undisclosed level of dietary salt. Our lab has shown that the neurogenic 
component of AngII-induced hypertension is dependent on dietary salt 
intake, and our primary interest was to determine whether the different 
methods would impact the expression of the “neurogenic phase” during 
the later stage of AngII infusion in rats consuming a high salt diet. 
In this study, we compared the reproducibility of the AngII-salt 
model of hypertension generated by subcutaneous administration of 
AngII using three different delivery methods. We compared the 
differences in the blood pressure profile of AngII-salt hypertension 
generated using Alzet, iPrecio, and Harvard infusion pumps attached to 
an implanted subcutaneous infusion catheter, and tested whether any 
differences between groups could be explained by differences in the 
change of plasma AngII levels over time.    
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6.2 Methods 
Experiments were performed in conscious, chronically instrumented 
rats in accordance with NIH guidelines. All acute and chronic 
experimental procedures were conducted after approval and by the 
institutional animal care and use committee of the University of 
Minnesota.  
6.2.1 Animal use and care  
Male Sprague-Dawley rats from Charles River Laboratories 
(Wilmington, MA) weighing 200-250g upon transfer to our facility were 
used in this study. Depending on the protocol (see below) rats were kept 
on a regular diet (Lab Diet 5012)) or switched to a special diet with 
variable NaCl content (Research Diets, Inc., New Brunswick, NJ). 
Animals were housed 2 per cage in a 12-12hr light-dark cycled room 
(8:30/20:30 cycle). Distilled water was available ad-libidum. Animals 
were allowed to acclimate for at least 1 week prior to surgery.   
6.2.2 Experimental Protocol 
 Rats were randomly assigned to one of two experiments. In the 
first experiment, rats were subjected to physiological and 
pharmacological stimuli known to increase or decrease plasma AngII 
levels, in order to establish a physiological range of endogenously 
generated plasma AngII. In the second experiment, AngII was 
administered for 2 weeks using three different subcutaneous infusion 
methods to establish the degree to which infusion modalities affect mean 
arterial pressure (MAP) and plasma AngII.  In both experiments, whole 
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blood was collected from conscious, freely moving rats via a jugular 
venous catheter, and plasma AngII was assayed using a commercial 
ELISA kit (described below). 
Experiment 1: Establishment of the physiological 
range of endogenously generated plasma AngII  
 The protocol for this experiment is shown in Figure 6.2. Rats 
were randomly assigned to 3 groups based on dietary NaCl content: 0%, 
0.1%, or 0.4%. Rats were given the respective diet and water ad-libidum 
throughout the study. Rats were acclimated to their diet for 7 days prior 
to surgical implantation of a jugular venous catheter for blood 
collection. Catheters were flushed daily with 50U/mL heparinized saline 
to maintain patency. These surgical procedures are described in detail 
below. 
Venous blood was collected 7 days after surgery and then again 7 
days later in 2 of the groups.  In rats fed a 0% NaCl diet, the loop 
diuretic drug furosemide (F4381, Sigma Aldrich, Co., St. Louis, MO), a 
known stimulant for renin release and subsequent increase in plasma 
AngII, was administered (50mg/kg, i.p.) and blood was collected ~3hrs 
later. Rats fed a 0.4% NaCl diet were subjected to another stimulus for 
renin release, 48hr water deprivation, 5 days after the initial blood 
collection and blood was then collected at the end of the 48hr period. 
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Experiment 2: Comparing the effect of 3 infusion 
methods on plasma AngII and arterial pressure 
during AngII-salt hypertension  
The protocol for this experiment is shown in 6.2. Rats were fed a 2% 
NaCl diet, given distilled water ad-libidum and randomly assigned to 
one of three groups based on the method of AngII delivery: 1) Alzet 
osmotic minipump (2ML2, DURECT, Corp., Cupertino, CA), 2) 
Harvard syringe pump (Model 935, Harvard Apparatus, South. Natick, 
MA) or 3) iPrecio micro infusion pump (SMP-200, Primetech, Corp., 
Tokyo, Japan). Rats were chronically instrumented with a DSI pressure 
transmitter and a jugular venous catheter. For rats in the Harvard 
group, a catheter was tunneled subcutaneously over the right flank area, 
exteriorized, and connected to a single channel hydraulic swivel (Model 
375/22PS, Instech Laboratories, Inc., Plymouth Meeting, PA). This was 
used later for subcutaneous delivery of AngII. All other rats were 
tethered to an in house made swivel. Rats were given 7-10 days to 
recover from the surgery. The surgical procedures are described in detail 
below. 
The study protocol consisted of 4 days of control followed by 14 days 
of AngII infusion. For the Alzet group, a second surgery was performed 
on the 5th day of the protocol for minipump implantation as previously 
described (66). In all groups, AngII (A9525, Sigma-Aldrich, Co.) 
dissolved in physiological saline was delivered at a 5uL/hr infusion rate 
and dosed at 150ng/kg/min based on body weight on control day 4. 
Blood was sampled on control day 1, and days 3, 7, and 14 of AngII for 
measurement of plasma AngII concentration  
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Arterial pressure (AP) data was collected using acquisition software 
from DSI (DataQuest ART Acquisition). The detailed acquisition setup 
has been described in detail previously (66). 10 second MAP and mean 
HR was calculated and stored every one minute using the built-in online 
analysis routine in the acquisition software. 
6.2.3 Surgical procedures 
Surgery was performed under isoflurane anesthesia (2.5% isoflurane 
in 100% O2 delivered via a nose cone at 1mL/min flow rate). After 
induction, rats were given atropine (0.2mg/kg, i.p., Baxter International, 
Inc., Deerfield, IL) for reduction of salivary and bronchial secretions, 
preoperative antibiotic prophylaxis (gentamicin, 0.05mL, i.m., Hospira, 
Inc., Lake Forest, IL), preoperative pain relief (ketoprofen, 5mg/kg, s.c., 
Fort Dodge Animal Health, Inc., Overland Park, KS) and placed on a 
heated surgical bench. Surgical instruments were heat sterilized and all 
implanted instruments were cold sterilized overnight in a solution of 
glutaraldehyde (Cidex Plus, Johnson & Johnson Services, Inc., New 
Brunswick, NJ).   
All rats were instrumented with a jugular venous catheter made from 
a Tygon tubing (0.02” I.D. x 0.06” O.D. Tygon Micro-Bore tubing S-54-
HL, Saint-Gobain Performance Plastics, Corp., Akron, OH) connected 
to a 6cm Silastic tube (0.02” I.D. x 0.037” O.D. Silastic Laboratory 
Tubing, Dow Corning, Corp., Midland, MI) using a 2cm polyethylene 
tube (PE50 Intramedic Polyethylene Tubing, Becton Dickinson and 
Company, Sparks, MD) coupler. A 1mm piece of Silastic tube (same as 
above) was slid 3cm from the tip of the Silastic portion of the catheter 
to serve as a cuff. A 2 cm incision was made slightly above the clavicles 
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along the mid-clavicular line. The external jugular vein was dissected 
free from the surrounding tissue. The distal end was permanently 
occluded with a knot and the proximal end was temporarily occluded 
while a small incision was made to gain access to the vascular lumen. 
The jugular catheter was advanced 3 cm from this incision towards the 
right atrium. The catheter was fixed in place by two knots above and 
below the cuff, tunneled subcutaneously through the chest and secured 
at three positions over the pectoral musculature before exteriorizing 
through a dorsal incision over the scapulae.   
 In addition to the jugular venous catheter, rats in Experiment 2 
were instrumented with a DSI pressure transmitter (TA11PA-C40, Data 
Sciences International (DSI), Saint Paul, MN) for measurement of 
arterial pressure as described previously (66). In the Harvard infusion 
group, a catheter (23g Tygon) was implanted subcutaneously such that 
the tip of the catheter was positioned over the animal’s right lower 
flank. In the iPrecio group, an iPrecio minipump filled with 
physiological saline was implanted subcutaneously over the animal’s 
right flank. The tip of the pump’s infusion catheter was tunneled across 
to the animal’s left flank. The body of the minipump was secured to the 
underlying subcutaneous tissue via the pump’s suture holes. 
The catheters were exteriorized through a skin incision over the 
scapulae, anchored to the underlying subcutaneous tissue using a 
circular surgical polyester mesh (PETKM14002, Textile Development 
Associates, Inc., Surgical Mesh Division, Brookfield, CN) which was 
implanted subcutaneously and sutured to the skin upon closure of the 
incision. The exteriorized catheters were threaded through a stainless 
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steel spring used for tethering the rat to a custom made or a commercial 
single channel hydraulic swivel mounted above their cage. 
Rats were given a minimum of 7 days to recover from surgery. 
Ketoprofen (5mg/kg, s.c., Fort Dodge Animal Health, Inc., Overland 
Park, KS) was administered daily for 3 days post surgery for pain 
management. Jugular venous catheters were flushed daily with lock 
solution (50U/mL heparinized saline; Hospira, Inc.) to ensure patency. 
6.2.4 Blood collection and separation of plasma 
0.35mL of whole blood was collected into a syringe containing 15uL 
of an inhibitor cocktail. The inhibitor cocktail consisted of a mixture of 
EDTA (125mM; E4884, Sigma-Aldrich, Co.), pepstatin-A (20ug/mL in 
methanol; 77170, Sigma-Aldrich, Co.), 1,10-Phenanthroline (8mg/mL; 
131377 Sigma-Aldrich, Co.), enalaprilat (80ug/mL in 50% ethanol; 
E9658, Sigma-Aldrich, Co.), APMSF (800ug/mL; A6664, Sigma-Aldrich, 
Co.), and 2-mercapto-ethanol (2%; M6250, Sigma-Aldrich, Co.) based on 
a protocol described previously (68). The inhibitor cocktail was prepared 
fresh prior to each sample collection from previously prepared stock 
solutions. Blood was chilled on ice immediately after collection. 
Following blood collection, 1mL of physiological saline was administered 
intravenously and the catheter was filled with lock solution. Blood was 
centrifuged at 2000g for 10min. Plasma was collected and re-centrifuged 
at 16000g for an additional 10min and stored at -80°C until assayed for 
AngII. On average, 180-200μL of plasma was recovered using this 
technique. 
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6.2.5 AngII assay 
Prior to the assay, plasma was thawed, acidified with 1% 
trifluoroacetic acid (TFA; 302031, Sigma-Aldrich, Co.) and centrifuged 
at 16000g for 10min. It was then purified through a C18 column (Y1000 
SEP-COLUMNS, Peninsula Laboratories, LLC, San Carlos, CA), 
washed with 1% TFA and eluted with a 60% solution of acetonitrile 
(34998, Sigma-Aldrich, Co.) containing 1% TFA. Samples were dried in 
a speed-vac centrifuge (heated to 50°C during the initial 4hrs of a 5hr 
run cycle) and resuspended in 200uL EIA buffer (from EIA kit). Sample 
pH was adjusted to pH 6~7 by adding microliter amounts of 1M sodium 
phosphate buffer and NaOH. Reconstituted samples were further diluted 
by 15-50% with addition of EIA buffer prior to measurement of AngII 
levels using a commercial ELISA kit (AngII EIA Kit #589301, Cayman 
Chemical Company, Ann Arbor, MI). All measurements were performed 
in duplicates.  
Absorbance at 450nm was measured using a plate reader. After 
loading the reporter (Ellman’s reagent) to each well, absorbance was 
serially measured at 10min intervals for a total of 1hr to ensure linearity 
of reaction. Absorbance reading from the 30min time point was used for 
final analysis.  
6.2.6 Data Analysis and Statistics 
AP and HR data for individual animals were averaged over a 24hr 
period. Duplicate absorbance readings from plasma samples were 
averaged and converted to units of pg/mL based on a standard provided 
with the kit. Grouped data are shown as mean±S.E.M. The effect of 
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dietary NaCl on plasma AngII level was analyzed by a one-way analysis 
of variance (ANOVA) followed by multiple comparisons (Holm-Sidak) 
versus control (0.4% NaCl). The effect of furosemide and 48hr water 
deprivation on 0% and 0.4% NaCl fed rats was analyzed by a paired t-
test. The effect of infusion method on plasma AngII, MAP, and HR was 
analyzed by a repeated measures ANOVA followed by a Holm-Sidak 
multiple comparisons test when appropriate. All aforementioned analysis 
was performed in SigmaPlot (version 11, Systat Software, Inc., 
Richmond, CA). 
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6.3 Results 
6.3.1 Experiment 1: Establishment of the 
physiological range of endogenously generated plasma 
AngII  
Plasma AngII responses to various stimuli showed physiologically 
consistent trends (Figure 6.3). Compared to plasma AngII level in rats 
fed a normal (0.4% NaCl) salt diet (9±2 pg/mL), plasma AngII 
increased ~5 fold to 50±10 pg/mL when dietary NaCl content was 
lowered to 0.1%. There was no further rise in plasma AngII levels (50±6 
pg/mL) when dietary NaCl content was further lowered to a minimum 
NaCl diet (0% NaCl). Acute furosemide injection to 0% NaCl rats to 
stimulate renin release and plasma AngII production caused a ~3 fold 
increase in plasma AngII levels to 170±30 pg/mL compared to baseline, 
and an ~18 fold increase compared to plasma levels from 0.4% NaCl 
rats. 48hr water deprivation in 0.4% NaCl rats caused an ~3 fold 
increase in plasma AngII levels to 31±3 pg/mL. Plasma AngII level in 
salt loaded rats with a 2% NaCl diet was 11±1 pg/mL, which was not 
significantly different from levels in 0.4% NaCl rats.  
6.3.2 Experiment 2: Comparing the effect of 3 
infusion methods on plasma AngII and arterial 
pressure during AngII-salt hypertension 
Arterial pressure and heart rate responses to AngII administration 
The three methods for chronic subcutaneous AngII infusion resulted 
in a subtle difference in the initial changes in MAP, but marked 
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differences in the final week of AngII-infusion (Figure 6.4; top panel). 
MAP at day 14 of AngII was highest in the iPrecio group 
(156±5mmHg) followed by Harvard (140±5mmHg), and Alzet 
(122±4mmHg). 
The largest single day rise in MAP occurred on day 1 of AngII 
infusion. The increase in MAP (compared to baseline) on AngII day 1 
was highest in the iPrecio group (24±2mmHg) followed by Alzet 
(17±2mmHg), and then the Harvard (11±1mmHg) group. Pressure rose 
gradually following this first day. Despite differences in the AngII day 1 
MAP response, the “slow pressor response” was similar between the 
iPrecio and Harvard group. The slow pressor response to AngII infusion 
was calculated by subtracting the MAP on days 1 to 14 of AngII from 
MAP on day 1 of AngII. This slow pressor response was markedly 
blunted in the Alzet group, which was due, in part, to the decrease in 
MAP that occurred in a subset of rats starting around day 8 of AngII. 
The slow pressor response from day 1 onward contributed 33±3mmHg, 
29±3mmHg, and 6±3mmHg of the total change in pressure seen at day 
14 of AngII in the iPrecio, Harvard, and Alzet groups respectively  
 The HR response to chronic AngII infusion (Figure 6.4; bottom 
panel) was also different among the three groups. HR decreased in all 
groups during the first week of AngII. The peak drop in HR occurred on 
days 3 and 4 of AngII for the Alzet and iPrecio groups, respectively, and 
on day 8 of AngII for the Harvard group. Following this nadir, HR 
tended to increase in all groups, and was most noticeable in the iPrecio 
group. HR on day 14 of AngII was 420±10BPM, 395±8BPM, and 
402±7BPM in the iPrecio, Harvard, and Alzet groups respectively. 
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6.3.3 Plasma AngII responses to AngII administration 
Figure 6.5 shows plasma AngII during control, days 3, 5, 7 and 14 of 
infusion and corresponding values for arterial pressure in the three 
groups. Plasma AngII during control was not statistically different 
between groups. Although the mean plasma AngII level during AngII 
administration for the entire infusion period (Figure 6.3; right panel), 
expressed as the combined average between days 3, 7, and 14 of AngII 
were not statistically different between the three groups (59±8, 62±7, 
71±8 pg/mL for Alzet, Harvard, and iPrecio, respectively), there were 
differences in the temporal profile of plasma AngII during AngII infusion 
between the three groups (Figure 6.5; top panel). Rats in the Alzet 
group showed a marked peak in plasma AngII on day 3 of AngII 
administration followed by a marked decline on days 7 and 14. In both 
Harvard and iPrecio groups, this peak in plasma AngII did not occur 
until day 7 of AngII. Similarly to the Alzet group, plasma AngII in the 
Harvard group declined markedly on day 14 of AngII; however, day 14 
plasma AngII levels in the iPrecio group remained near day 7 levels. 
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6.4 Discussion 
Our collaborators and we have years of experience using Alzet 
minipumps to study the AngII-salt model of hypertension (62, 63, 64, 
66, 88, 115). During this time we found that the arterial pressure 
response to AngII in random subsets of animals begins to decline 
gradually starting at the second week of AngII-infusion. This results in a 
blunting of the slow-pressor response and reduced final blood pressure in 
control animals, making comparison and interpretation of cardiovascular 
responses in the treatment groups difficult. Other researchers using this 
model (AngII induced hypertension with Alzet minipumps) in mice and 
rats have voiced similar concerns (personal communications). Indeed, we 
formally discussed this issue in 2011 at a workshop of the American 
Physiological Society on small animal instrumentation but this issue had 
not been addressed in the literature.  
Based on a recently published article showing subtle differences in 
the initial arterial pressure profile of AngII-induced hypertension using 
Alzet pumps and a new implantable mechanical pump (iPrecio) (107), 
we hypothesized that the marked variability in slow-pressor response of 
the AngII-salt model was mainly due to factors inherent in the 
performance of Alzet minipumps. Therefore, we compared the arterial 
pressure profile of AngII-salt hypertension generated using Alzet, 
iPrecio, and an external infusion pump (Harvard) connected to a 
subcutaneously implanted catheter. We also measured plasma AngII 
levels during control and days 3, 7, and 14 of AngII, as we reasoned that 
differences in the pump’s ability to maintain the expected delivery rate 
of AngII would be a main underlying cause for any between pump 
differences.  
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6.4.1 Response of plasma AngII to subcutaneous 
infusion: Comparison to endogenously generated 
AngII 
Using a commercially available AngII ELISA assay, plasma AngII 
concentration in rats fed a “regular” salt diet (~0.4% NaCl) were 
comparable to values reported in the literature, which range between 11 
– 50 pg/mL in normal rats (18, 47, 99, 122). In rats fed a 2% NaCl diet, 
plasma AngII levels did not decrease any further compared to 0.4% rats, 
despite the 5-fold increase in dietary salt intake. The absence of a 
statistically distinguishable difference could have been due to a 
limitation in the sensitivity of the assay, but it nevertheless suggests 
that rats fed a “regular” diet are at the tail end of a plasma AngII vs. 
salt intake response curve. In general, when examining all three methods 
of subcutaneous AngII administration at 150ng/kg/min, plasma AngII 
concentration in 2%NaCl rats increased ~5 fold. This response was well 
within the physiological range of AngII as compared to levels seen in 
salt deplete rats fed a 0.1% or minimum (0%) NaCl diet. Even at peak 
levels observed on day 3 of AngII in Alzet rats, plasma AngII values 
were within physiologically attainable range as values were below those 
seen in salt depleted rats acutely treated with furosemide.  
In comparison, plasma AngII concentration reported by others in 
AngII-induced hypertension ranged from 26pg/mL in rats given AngII at 
100ng/kg/min (99), 34pg/mL for 175ng/kg/min (18), 27-157pg/mL for 
200ng/kg/min (18, 47), 79pg/mL for 350ng/kg/min (18), and 101pg/mL 
for 500ng/kg/min (18). In most of these cases, plasma AngII levels 
during AngII infusion were not statistically distinguishable from control 
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levels. In those that reported a statistically significant change, the fold 
change from control levels was 2x for 100ng/kg/min (99), 3x for 
200ng/kg/min (122), and 6x for 500ng/kg/min (18). Although the rise 
in plasma AngII measured during AngII-salt hypertension was higher in 
our study for the given delivery rate of AngII, direct between study 
comparison is difficult to make due to differences in the level of dietary 
salt used in this (2% NaCl) and other studies (likely ~0.4%), and the 
high degree of variability in the reported values, both within and 
between studies. Between study variations are likely due to differences 
in the AngII assay.  
6.4.2 Explanations for differences between methods of 
delivery for plasma AngII and cardiovascular 
responses 
 In the present study, the only difference between groups was the 
method of subcutaneous AngII delivery. The concentration and 
composition of the AngII infusate, and the theoretical flow rate of AngII 
delivery was identical in all groups. Therefore, differences in the arterial 
pressure (and plasma AngII response) are not likely to be explained by 
degradation of AngII within the pump. Indeed, other researchers have 
compared before implant and after explant levels of AngII and found 
that there were no detectable differences between the two levels (47). 
Griffin and colleagues have suggested that large within study 
variability in plasma AngII concentration in models of AngII-induced 
hypertension, specifically when Alzet pumps are used, could potentially 
be due to intermittent pumping that result in unpredictable fluctuations 
in plasma AngII (47). Indeed, we found that Alzet rats had a marked 
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spike in plasma AngII on Day 3 of AngII administration, which rapidly 
trailed off over the subsequent period of AngII administration. This 
pattern was not observed in rats in which AngII was administered by a 
pump in which flow rate is mechanically fixed (iPrecio and Harvard 
rats). It may be that for the Alzet pumps, there is an initially higher 
flow rate (60) that corresponds with osmotically driven compression of 
the pump bladder, and this rate then decreases over time. This may be 
one explanation for the “non-responder” profile of the Alzet rats; a rapid 
fall off in pump flow rate that does not occur with a “mechanical” pump. 
It should be noted however that although a higher degree of variability 
in plasma AngII levels on day 3 of AngII was observed in Alzet rats, the 
variability on days 7 and 14 of AngII were comparable among the three 
groups. Thus, other factors may contribute to the higher variability of 
plasma AngII during AngII-induced hypertension. 
Compared to the previously published “pilot” study (107) which 
showed a slight pump dependent difference in the initial profile of MAP 
during AngII-induced hypertension, differences between Alzet and 
iPrecio pumps, in this study, were larger in magnitude, and especially 
pronounced during the second week of AngII infusion. Based on the level 
of the slow-pressor response, measured in terms of day to day change in 
pressure averaged over days 2 to 14 of AngII, final level of MAP, and 
the variability in those values, the iPrecio group displayed the most 
“robust” AngII-salt hypertension phenotype during the 2 week protocol. 
The Harvard group had an intermediate final level of MAP, but a 
similar slow-pressor response to iPrecio. The Alzet group had the lowest 
final level of MAP, and a significantly blunted slow-pressor response 
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due, in part, to a gradual drop in MAP in a subset of rats during the 
second week of AngII-infusion.  
There were notable between pump differences in the day 1 level of 
MAP, which ultimately impacted the final level of MAP at the end of 
the 2-week infusion protocol. Day 1 MAP in the Harvard group was 
lowest amongst the three groups. One likely explanation for this lower 
level of MAP is the difficulty in adjusting the infusion rate of the pump 
to match that of Alzet and iPrecio pumps. Although the Harvard pump 
was calibrated to an infusion rate of 5μL/hr based on accurate 
measurements of syringe diameter and displacement rate of the plunger, 
it is possible that compliance within couplings at the infusion line, and 
undetectable leakage in the hydraulic swivel from elevated back-pressure 
due to material buildup at tip of the implanted catheter or kink at the 
site of exteriorization, caused a lower volume to be delivered compared 
to the expected rate.  
Although differences in day 3 plasma AngII levels between Harvard 
and iPrecio do not reflect a lower AngII delivery rate in the Harvard 
group, baroreflex and negative feedback effect of AngII on renin 
secretion could have resulted in lower plasma AngII levels in the iPrecio 
group, thus masking the initial effect of differences in the infusion rate. 
This uncoupling of plasma AngII-levels and MAP is also evident on day 
3 values in Alzet rats compared to iPrecio. Although AngII-levels were 
significantly higher in the Alzet group, there were no significant 
differences in MAP compared to iPrecio. One possibility is a higher 
initial pumping rate in Alzet pumps, as our protocol has a short pre-
equilibration step (~2-3hrs) and no warming step prior to pump 
implantation, both reported to affect initial pump performance when 
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used in acute settings (60). The lower day 1 change in MAP compared 
to iPrecio makes this scenario unlikely, however, it is possible that 
accelerated pumping is delayed. The lack of a difference in MAP on day 
3 of AngII compared to iPrecio could be due to compensatory 
mechanisms that are able to buffer the pressor effect of a higher level of 
plasma AngII.  
6.4.3 Differences in day 1 MAP response to AngII do 
not predict the magnitude of the subsequent slow 
pressor response  
If differences in the infusion rate of AngII between groups were 
responsible for differences in the increase of MAP over time, and the 
infusion rate is constant, one would predict these changes should appear 
on the first day of AngII administration and remain for the duration of 
the protocol. However, this was not the case. Even though the MAP 
response on Day 1 of AngII administration was lower in the Harvard 
group compared to iPrecio, the subsequent rate of rise of MAP over 
time was the same. On the other hand, the MAP response on Day 1 in 
the Alzet group was similar to the Harvard group, but the subsequent 
rate of rise of MAP was significantly less. This suggests that the 
blunting and disappearance of the slow-pressor response after day 7 of 
AngII in the Alzet group is due to problems intrinsic to the use of Alzet 
pumps in this particular context. There are several explanations for to 
this result. A gradual decrease in the pumping rate or a reduction in the 
effective concentration of AngII in the infusate due to degradation 
within the pump could have resulted in a gradual reduction in the 
delivered dose of AngII. Alternatively, it has been proposed that fibrotic 
 177 
changes or increased degradation of AngII secondary to an inflammatory 
reaction around the site of pump implant result in reduced AngII 
absorption (15). Although we did not investigate these possibilities, we 
reasoned that either scenario could have resulted in measurable changes 
in plasma AngII levels paralleling changes in arterial pressure. 
Consistent with this concept, there was a downward trend in plasma 
AngII levels in Alzet rats reflected by the significantly lower plasma 
AngII levels on days 7 and 14 of AngII following its day 3 peak.  
6.4.4 Summary and Perspectives 
AngII-induced hypertension has been a popular model due to its 
relative ease to generate a hypertensive phenotype. However, comparing 
results between laboratories are difficult due to the variety of protocols 
in use, ranging from differences in dose of AngII, route of AngII 
administration, and level of dietary salt. The findings in this study 
shows that Alzet pumps may add another source of variability due to 
characteristics inherent to the pump. The use of mechanical infusion 
devices, either implantable (iPrecio) or external (syringe pump), may 
remove this pump dependent source of variability and result in a more 
reproducible and consistent AngII-induced hypertension phenotype. 
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6.5 Figures 
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Figure 6.1. Spontaneous drop in MAP during AngII-
salt hypertension using Alzet pumps 
 
Data from a separate study collected from rats fed a 2% NaCl diet 
subjected to a 2 week infusion of AngII (150ng/kg/min, s.c.) using Alzet 
osmotic minipumps (model 2ML2). Half of rats showed a typical slow-
pressor response (“responder”, black circles; n=10). In the other half, 
MAP gradually dropped during the second week of AngII-infusion (“non-
responder”, white circles; n=9). Error bars are S.E.M. 
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Figure 6.1 
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Figure 6.2. Description of study protocol 
 
(Top Panel): Protocol for experiment 1. In the first half of the 
protocol, blood was sampled from 3 groups of rats fed a 0.4%, 0.1%, or a 
minimum NaCl diet (0%) to determine the effect of dietary NaCl on 
plasma AngII levels. In the second half of the protocol, 0.4% rats were 
further subjected to a 48hr water deprivation period, and 0% rats were 
given an acute injection of furosemide to determine the range of plasma 
AngII responses attainable with further physiological and 
pharmacological stimuli to the renin-angiotensin-aldosterone axis. 
(Bottom Panel): Protocol for the main experiment in which 3 groups 
of rats fed a 2%NaCl diet were subjected to a 2 week subcutaneous 
infusion of AngII using a Harvard external infusion pump (model 935), 
Alzet osmotic minipumps (model 2ML2), or iPrecio pumps. Blood was 
collected on control day 1, and days 3, 7, and 14 of AngII for 
measurement of plasma AngII levels. 
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Figure 6.2 
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Figure 6.3. Changes in plasma AngII levels in 
response to physiological salt loading, water 
deprivation, and pharmacological salt depletion 
 
(Left Panel): Results from experiment 1. Data for the 2% NaCl 
diet group is the control period plasma AngII level from experiment 2 
averaged across all 3 groups of rats (i.e. Alzet, Harvard and iPrecio). N 
= 26, 8, 8, 8 for 2%, 0.4%, 0.1%, and 0% salt groups, respectively. 
(Right Panel): Plasma AngII levels during chronic infusion of AngII 
(150ng/kg/min, s.c.) using Harvard (n=9), Alzet (n=12), or iPrecio 
(n=10) pumps. The plotted plasma AngII level represents the average 
from days 3, 7, and 14 of AngII infusion. There were no between group 
differences. (†) denotes statistical significance compared to the 0.4% 
NaCl group. 
 (∗) denotes statistically significant effect after furosemide or water 
deprivation within the given dietary NaCl group. (‡) denotes 
statistically significant increase in plasma AngII levels during AngII 
infusion in Harvard, Alzet, and iPrecio groups compared to their 
respective control levels. Statistical significance was set at p<0.05 or less 
with post-hoc comparisons using the appropriate correction for 
significance level. Error bars are S.E.M. 
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Figure 6.3 
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Figure 6.4. Differences in MAP profile of AngII-salt 
hypertension generated using Alzet, Harvard or 
iPrecio pumps 
 
24hr mean arterial pressure (MAP; top panel) and heart rate (HR; 
bottom panel) during control and 2 weeks of AngII infusion using 
Harvard (white circle; n=12), Alzet (black circle; n=15), or iPrecio 
(black triangle; n=10) pumps in rats fed a 2% NaCl diet. MAP on days 
1 through 14 of AngII was significantly elevated compared to control 
day 3 in all groups. (†), (‡), and (#) denote significant within group 
differences compared to values on control day 3 in Alzet, Harvard, and 
iPrecio groups, respectively. (∗), (§), and (¶) denote significant 
differences between iPrecio and Alzet, iPrecio and Harvard, and Harvard 
and Alzet, respectively. Statistical significance was set at p<0.05 or less 
in post-hoc comparisons using appropriate correction for significance 
level. Error bars are S.E.M.  
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Figure 6.4 
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Figure 6.5. Changes in plasma AngII levels during 
AngII-salt hypertension generated using Alzet, 
Harvard or iPrecio pumps 
 
Plasma AngII levels (top panel) measured on control day 1, and days 
3, 7, and 14 of AngII in Harvard (white circle; n=9), Alzet (black circle; 
n=12), and iPrecio (black triangle; n=10) groups. 24hr MAP on 
corresponding days is also shown (bottom panel). (†), and (‡), denote 
significant within group change from control in Alzet, and iPrecio 
groups, respectively. (∗), (§), and (¶) denote significant differences 
between iPrecio and Alzet, iPrecio and Harvard, and Harvard and Alzet, 
respectively. Statistical significance was set at p<0.05 or less in post-hoc 
comparisons using appropriate correction for significance level. Error 
bars are S.E.M. 
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Figure 6.5 
 
 
 
